	<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
	<channel rdf:about="https://biorxiv.org">
	<admin:errorReportsTo rdf:resource="mailto:biorxiv@cshlpress.edu"/>
	<title>bioRxiv Channel: <? echo $gname; ?></title>
	<link>https://biorxiv.org</link>
	<description>
	This feed contains articles for bioRxiv Channel "<? echo $gname; ?>"
	</description>

		<items>
	<rdf:Seq>
		</rdf:Seq>
	</items>
	<prism:eIssn/>
	<prism:publicationName>bioRxiv</prism:publicationName>
	<prism:issn/>

	<image rdf:resource=""/>
	</channel>
	<image rdf:about="">
	<title>bioRxiv</title>
	<url/>
	<link>https://biorxiv.org</link>
	</image>
	<item rdf:about="https://biorxiv.org/cgi/content/short/833467v1?rss=1">
<title>
<![CDATA[
Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/P38 signaling 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/833467v1?rss=1"
</link>
<description><![CDATA[
Benign peripheral nerve sheath tumors are the clinical hallmark of Neurofibromatosis Type 1. They account for substantial morbidity in NF1 and are difficult to manage. Cutaneous (CNF) and plexiform neurofibromas (PNF) share identical histology, but maintain different growth rates and risk of malignant conversion. The reasons for their disparate clinical behavior are not well explained on the basis of recent genome or transcriptome profiling studies. We hypothesized that CNFs and PNFs are epigenetically distinct tumor types that exhibit differential signaling due to genome-wide and site-specific methylation events. We interrogated the methylation profiles of 45 CNFs and 17 PNFs (Illumina EPIC 850K) using normal tissue controls from NF1 subjects. Based on these profiles, we confirm that CNFs and PNFs are epigenetically distinct tumors with broad differences in higher order chromatin states, and specific methylation events altering genes involved in key biological and cellular processes such as inflammatory mediator regulation of TRP channels, RAS/MAPK signaling, actin cytoskeleton rearrangement, and oxytocin signaling. Based our identification of 2 separate DMRs associated with alternative leading exons in MAP2K3, we demonstrate differential RAS/MKK3/P38 signaling between CNFs and PNFs. Epigenetic reinforcement of RAS/MKK/P38 was a defining characteristic of CNFs leading to pro-inflammatory signaling and chromatin conformational changes, whereas PNFs signaled predominantly through RAS/ERK. Tumor size also correlated with specific CpG methylation events. Taken together, these findings confirm that epigenetic regulation of RAS signaling fates accounts for observed differences in CNF and PNF clinical behavior. CNFs may also respond differently than PNFs to RAS-targeted therapeutics raising the possibility of targeting P38-mediated inflammation for CNF treatment.
]]></description>
<dc:creator>Grit, J. L.</dc:creator>
<dc:creator>Johnson, B. K.</dc:creator>
<dc:creator>Essenburg, C. J.</dc:creator>
<dc:creator>Dischinger, P. S.</dc:creator>
<dc:creator>Campbell, S.</dc:creator>
<dc:creator>Triche, T. J.</dc:creator>
<dc:creator>Graveel, C. R.</dc:creator>
<dc:creator>Steensma, M. R.</dc:creator>
<dc:date>2019-12-02</dc:date>
<dc:identifier>doi:10.1101/833467</dc:identifier>
<dc:title><![CDATA[Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/P38 signaling]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2019-12-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2022.02.03.479021v1?rss=1">
<title>
<![CDATA[
Therapeutic vulnerability to ATR inhibition in concurrent NF1 and ATRX-deficient high-grade solid tumors 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2022.02.03.479021v1?rss=1"
</link>
<description><![CDATA[
Subsets of Neurofibromatosis Type 1 (NF1)-associated solid tumors have been shown to display high frequencies of ATRX mutations and presence of alternative lengthening of telomeres (ALT). In addition, a potential biologic vulnerability of ALT-positive cancer cells is ATR inhibition, a regulator of homologous recombination. We studied the phenotype of combined NF1 and ATRX deficiency in malignant solid tumors. For these experiments, cell lines derived from NF1-deficient sporadic glioblastomas (U251, SF188), a NF1-associated ATRX mutant glioblastoma cell line (JHH-NF1-GBM1), a NF1-derived sarcoma cell line (JHH-CRC65), and two NF1-deficient MPNST cell lines (ST88-14, NF90.8) were utilized. Cancer cells were treated with ATR inhibitors (AZD6738 and VE-822), in vitro, with or without a MEK inhibitor (AZD6244, selumetinib) or temozolomide. In contrast to the glioma cell line SF188, combined ATRX knockout (KO) and TERC KO led to ALT-like properties and sensitized U251 glioma cells to ATR inhibition (AZD6738 and VE-822) in vitro and in vivo. In addition, ATR inhibitors sensitized U251 cells to temozolomide, but not MEK inhibition (AZD6244), irrespective of ATRX level manipulation; whereas, the JHH-NF1-GBM1 cell line (ATRX loss/ALT-positive) demonstrated sensitivity to ATR inhibition (AZD6738), but not temozolomide. Similar effects were noted using the MPNST cell line NF90.8 after combined ATRX knockdown and TERC KO; however, not in the MPNST cell line ST88-14. Taken together, our study supports the feasibility of targeting the ATR pathway in subsets of NF1-deficient and associated tumors. Tumors with pre-existing ALT, or that subsequently develop ALT after ATRX downregulation, are particularly vulnerable to this therapeutic approach.
]]></description>
<dc:creator>Yuan, M.</dc:creator>
<dc:creator>Eberhart, C. G.</dc:creator>
<dc:creator>Pratilas, C. A.</dc:creator>
<dc:creator>Blakeley, J. O.</dc:creator>
<dc:creator>Davis, C.</dc:creator>
<dc:creator>Stojanova, M.</dc:creator>
<dc:creator>Reilly, K.</dc:creator>
<dc:creator>Meeker, A. K.</dc:creator>
<dc:creator>Heaphy, C. M.</dc:creator>
<dc:creator>Rodriguez, F. J.</dc:creator>
<dc:date>2022-02-03</dc:date>
<dc:identifier>doi:10.1101/2022.02.03.479021</dc:identifier>
<dc:title><![CDATA[Therapeutic vulnerability to ATR inhibition in concurrent NF1 and ATRX-deficient high-grade solid tumors]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2022-02-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2022.04.29.490078v1?rss=1">
<title>
<![CDATA[
Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2022.04.29.490078v1?rss=1"
</link>
<description><![CDATA[
Malignant peripheral nerve sheath tumors (MPNST) are aggressive soft tissue sarcomas that often develop in patients with neurofibromatosis type 1 (NF1-MPNST), but can occur sporadically. Through a multi-institution collaboration, we have developed 13 NF1-associated MPNST patient-derived xenografts (PDX). Genomic analysis of the PDX-tumor pairs identified somatic mutations in NF1 (61%), SUZ12 (61%), EED (15%), and TP53 (15%), and chromosome 8 (Chr8) gain (77%), consistent with published data. Pre-clinical models that capture this molecular heterogeneity are needed to identify and prioritize effective drug candidates for clinical translation. Here, we describe the successful development of a medium-throughput ex vivo 3D microtissue model with several advantages over 2D cell line growth, which can be utilized to predict drug response in vivo. Herein, we present proof-of-principle of this PDX-to-microtissue system, using four genomically representative MPNST and three drugs. This work highlights the development of a novel ex vivo to in vivo preclinical platform in MPNST that successfully captures the genomic diversity observed in patients and represents a resource to identify future therapeutic strategies.
]]></description>
<dc:creator>Bhatia^, H.</dc:creator>
<dc:creator>Larsson^, A. T.</dc:creator>
<dc:creator>Calizo^, A.</dc:creator>
<dc:creator>Pollard, K.</dc:creator>
<dc:creator>Zhang, X.</dc:creator>
<dc:creator>Conniff, E.</dc:creator>
<dc:creator>Tibbitts, J. F.</dc:creator>
<dc:creator>Osum, S. H.</dc:creator>
<dc:creator>Williams, K. B.</dc:creator>
<dc:creator>Crampton, A. L.</dc:creator>
<dc:creator>Jubenville, T.</dc:creator>
<dc:creator>Schefer, D.</dc:creator>
<dc:creator>Yang, K.</dc:creator>
<dc:creator>Lyu, Y.</dc:creator>
<dc:creator>Bade, J.</dc:creator>
<dc:creator>Pino, J. C.</dc:creator>
<dc:creator>Gosline, S. J.</dc:creator>
<dc:creator>Pratilas, C. A.</dc:creator>
<dc:creator>Largaespada, D. A.</dc:creator>
<dc:creator>Wood, D. K.</dc:creator>
<dc:creator>Hirbe, A. C.</dc:creator>
<dc:date>2022-05-02</dc:date>
<dc:identifier>doi:10.1101/2022.04.29.490078</dc:identifier>
<dc:title><![CDATA[Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2022-05-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2020.01.13.904771v1?rss=1">
<title>
<![CDATA[
Integrative analysis identifies candidate tumor microenvironment and intracellular signaling pathways that define tumor heterogeneity in NF1 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2020.01.13.904771v1?rss=1"
</link>
<description><![CDATA[
Neurofibromatosis type 1 is a monogenic syndrome that gives rise to numerous symptoms including cognitive impairment, skeletal abnormalities, and growth of benign nerve sheath tumors. Nearly all NF1 patients develop cutaneous neurofibromas (cNFs), which occur on the skin surface, while 40-60% of patients develop plexiform neurofibromas (pNFs) which are deeply embedded in the peripheral nerves. Patients with pNFs have a [~]10% lifetime chance of these tumors becoming malignant peripheral nerve sheath tumors (MPNSTs). These tumors have a severe prognosis and few treatment options other than surgery. Given the lack of therapeutic options available to patients with these tumors, identification of druggable pathways or other key molecular features could aid ongoing therapeutic discovery studies. In this work, we used statistical and machine learning methods to analyze 77 NF1 tumors with genomic data to characterize key signaling pathways that distinguish these tumors and identify candidates for drug development. We identified subsets of latent gene expression variables that may be important in the identification and etiology of cNFs, pNFs, other neurofibromas, and MPNSTs. Furthermore, we characterized the association between these latent variables and genetic variants, immune deconvolution predictions, and protein activity predictions.
]]></description>
<dc:creator>Banerjee, J.</dc:creator>
<dc:creator>Allaway, R. J.</dc:creator>
<dc:creator>Taroni, J. N.</dc:creator>
<dc:creator>Baker, A.</dc:creator>
<dc:creator>Zhang, X.</dc:creator>
<dc:creator>Moon, C. I.</dc:creator>
<dc:creator>Blakeley, J. O.</dc:creator>
<dc:creator>Guinney, J.</dc:creator>
<dc:creator>Hirbe, A.</dc:creator>
<dc:creator>Greene, C. S.</dc:creator>
<dc:creator>Gosline, S. J.</dc:creator>
<dc:date>2020-01-14</dc:date>
<dc:identifier>doi:10.1101/2020.01.13.904771</dc:identifier>
<dc:title><![CDATA[Integrative analysis identifies candidate tumor microenvironment and intracellular signaling pathways that define tumor heterogeneity in NF1]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2020-01-14</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2019.12.19.871897v1?rss=1">
<title>
<![CDATA[
A clinically and genomically annotated nerve sheath tumor biospecimen repository. 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2019.12.19.871897v1?rss=1"
</link>
<description><![CDATA[
Nerve sheath tumors occur as a heterogeneous group of neoplasms in patients with neurofibromatosis type 1 (NF1). The malignant form represents the most common cause of death in people with NF1, and even when benign, these tumors can result in significant disfigurement, neurologic dysfunction, and a range of profound symptoms. Lack of human tissue across the peripheral nerve tumors common in NF1 has been a major limitation in the development of new therapies. To address this unmet need, we have created an annotated collection of patient tumor samples, patient-derived cell lines, and patient-derived xenografts, and carried out high-throughput genomic and transcriptomic characterization to serve as a resource for further biologic and preclinical therapeutic studies. In this work, we release genomic and transcriptomic datasets comprised of 55 tumor samples derived from 23 individuals, complete with clinical annotation. All data are publicly available through the NF Data Portal and at http://synapse.org/jhubiobank.
]]></description>
<dc:creator>Pollard, K.</dc:creator>
<dc:creator>Banerjee, J.</dc:creator>
<dc:creator>Doan, X.</dc:creator>
<dc:creator>Wang, J.</dc:creator>
<dc:creator>Guo, X.</dc:creator>
<dc:creator>Allaway, R. J.</dc:creator>
<dc:creator>Langmead, S.</dc:creator>
<dc:creator>Slobogean, B.</dc:creator>
<dc:creator>Meyer, C.</dc:creator>
<dc:creator>Loeb, D.</dc:creator>
<dc:creator>Morris, C.</dc:creator>
<dc:creator>Belzberg, A.</dc:creator>
<dc:creator>Blakeley, J. O.</dc:creator>
<dc:creator>Rodriguez, F.</dc:creator>
<dc:creator>Guinney, J.</dc:creator>
<dc:creator>Gosline, S. J.</dc:creator>
<dc:creator>Pratilas, C. A.</dc:creator>
<dc:date>2019-12-19</dc:date>
<dc:identifier>doi:10.1101/2019.12.19.871897</dc:identifier>
<dc:title><![CDATA[A clinically and genomically annotated nerve sheath tumor biospecimen repository.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2019-12-19</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2022.05.03.490481v1?rss=1">
<title>
<![CDATA[
Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2022.05.03.490481v1?rss=1"
</link>
<description><![CDATA[
Malignant peripheral nerve sheath tumour (MPNST) is an aggressive soft-tissue sarcoma that arises in peripheral nerves. MPNST occurs either sporadically or in people with neurofibromatosis type 1 (NF1), a common cancer predisposition syndrome caused by germline pathogenic variants in NF1. Although MPNST is the most common cause of death and morbidity for individuals with NF1, the molecular underpinnings of MPNST pathogenesis remain unclear. Here, we report the analysis of whole-genome sequencing, multi-regional exome sequencing, transcriptomic and methylation profiling data for 95 MPNSTs and precursor lesions (64 NF1-related; 31 sporadic) from 77 individuals. Early events in tumour evolution include biallelic inactivation of NF1 followed by inactivation of CDKN2A and in some cases also TP53 and polycomb repressive complex 2 (PRC2) genes. Subsequently, both sporadic and NF1-related MPNSTs acquire a high burden of somatic copy number alterations (SCNAs). Our analysis revealed distinct pathways of tumour evolution and immune infiltration associated with inactivation of PRC2 genes and H3K27 trimethylation (H3K27me3) status. Tumours with loss of H3K27me3 evolve through extensive chromosomal losses with retention of chromosome 8 heterozygosity followed by whole genome doubling and chromosome 8 amplification. These tumours show lower levels of immune cell infiltration with low cytotoxic activity and low expression of immune checkpoints. In contrast, tumours with retention of H3K27me3 evolve through extensive genomic instability in the absence of recurrent alterations and exhibit an immune cell-rich phenotype. Specific SCNAs detected in both tumour samples and cell-free DNA (cfDNA) act as a surrogate for loss of H3K27me3 and immune infiltration, and predict prognosis. Our results suggest that SCNA profiling of tumour or cfDNA could serve as a biomarker for early diagnosis and to stratify patients into prognostic and treatment-related subgroups.
]]></description>
<dc:creator>Cortes-Ciriano, I.</dc:creator>
<dc:creator>Steele, C. D.</dc:creator>
<dc:creator>Piculell, K. G.</dc:creator>
<dc:creator>Al-Ibraheemi, A.</dc:creator>
<dc:creator>Eulo, V.</dc:creator>
<dc:creator>Bui, M. M.</dc:creator>
<dc:creator>Chatzipli, A.</dc:creator>
<dc:creator>Dickson, B. C.</dc:creator>
<dc:creator>Borcherding, D. C.</dc:creator>
<dc:creator>Feber, A.</dc:creator>
<dc:creator>Galor, A.</dc:creator>
<dc:creator>Hart, J.</dc:creator>
<dc:creator>Jones, K. B.</dc:creator>
<dc:creator>Jordan, J. T.</dc:creator>
<dc:creator>Kim, R. H.</dc:creator>
<dc:creator>Lindsay, D.</dc:creator>
<dc:creator>Miller, C.</dc:creator>
<dc:creator>Nishida, Y.</dc:creator>
<dc:creator>Proszek, P.</dc:creator>
<dc:creator>Serrano, J.</dc:creator>
<dc:creator>Sundby, R. T.</dc:creator>
<dc:creator>Szymanski, J. J.</dc:creator>
<dc:creator>Ullrich, N. J.</dc:creator>
<dc:creator>Viskochil, D.</dc:creator>
<dc:creator>Wang, X.</dc:creator>
<dc:creator>Snuderl, M.</dc:creator>
<dc:creator>Park, P. J.</dc:creator>
<dc:creator>Flanagan, A. M.</dc:creator>
<dc:creator>Hirbe, A. C.</dc:creator>
<dc:creator>Pillay, N.</dc:creator>
<dc:creator>Miller, D. T.</dc:creator>
<dc:date>2022-05-05</dc:date>
<dc:identifier>doi:10.1101/2022.05.03.490481</dc:identifier>
<dc:title><![CDATA[Genomic patterns of malignant peripheral nerve sheath tumour (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2022-05-05</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2021.05.03.442481v1?rss=1">
<title>
<![CDATA[
A genetic mouse model with postnatal Nf1 and p53 loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2021.05.03.442481v1?rss=1"
</link>
<description><![CDATA[
BackgroundMalignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas. Somatic inactivation of NF1 and cooperating tumor suppressors, including CDKN2A/B, PRC2, and p53, is found in most MPNST. Inactivation of the LATS1/2 kinases of the Hippo pathway was recently shown to cause tumors resembling MPNST histologically, although Hippo pathway mutations are rarely found in MPNST. Because existing genetically engineered mouse (GEM) models of MPNST do not recapitulate some of the key genetic features of human MPNST, we aimed to establish a mouse MPNST model that recapitulated the human disease genetically, histologically, and molecularly.

MethodsWe combined two genetically modified alleles, an Nf1;Trp53 cis-conditional allele and an inducible Plp-CreER allele (NP-Plp), to model the somatic, possibly postnatal, mutational events in human MPNST. We also generated conditional Lats1;Lats2 knockout mice. We performed histopathologic analysis of mouse MPNST models and transcriptomic comparison of mouse models and human nerve sheath tumors.

ResultsPostnatal Nf1;Trp53 cis-deletion resulted in GEM-MPNST that was histologically more similar to human MPNST than the widely used germline Nf1;Trp53 cis-heterozygous (NPcis) model and showed partial loss of H3K27me3. At the transcriptome level, Nf1;p53-driven GEM-MPNST were distinct from Lats-driven GEM-MPNST and resembled human MPNST more closely than do Lats-driven tumors.

ConclusionsThe NP-Plp model recapitulates human MPNST genetically, histologically, and molecularly.

Key PointsO_LIPostnatal Nf1;p53 cis-deletion in NP-Plp mice results in tumors similar to MPNST.
C_LIO_LIThe transcriptomes of Nf1;p53-driven and Lats-driven MPNST models are distinct.
C_LIO_LINP-Plp model resembles human MPNST genetically, histologically, and molecularly.
C_LI

Importance of the StudyMalignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas with a poor prognosis and limited treatment options. Existing genetically engineered mouse (GEM) models of MPNST do not recapitulate some of the key genetic features of human MPNST. To model the somatic, possibly postnatal, mutational events seen in MPNST patients, we generated a GEM-MPNST model by combining two genetically modified alleles, an Nf1;Trp53 cis-conditional allele and a Plp-CreER allele. Our histologic and transcriptomic analyses showed that this NP-Plp model resembles human MPNST genetically, histologically, and molecularly--more so than the widely used NPcis model and the recently published Lats-driven model. The NP-Plp model is genetically simple, making it easy to maintain and an ideal platform for preclinical studies. Given its tamoxifen-inducible nature, this model can be used to study the time/stage dependency of the tumorigenic potential of Schwann cells.
]]></description>
<dc:creator>Inoue, A.</dc:creator>
<dc:creator>Janke, L. J.</dc:creator>
<dc:creator>Gudenas, B. L.</dc:creator>
<dc:creator>Jin, H.</dc:creator>
<dc:creator>Fan, Y.</dc:creator>
<dc:creator>Pare, J.</dc:creator>
<dc:creator>Clay, M. R.</dc:creator>
<dc:creator>Northcott, P. A.</dc:creator>
<dc:creator>Hirbe, A. C.</dc:creator>
<dc:creator>Cao, X.</dc:creator>
<dc:date>2021-05-04</dc:date>
<dc:identifier>doi:10.1101/2021.05.03.442481</dc:identifier>
<dc:title><![CDATA[A genetic mouse model with postnatal Nf1 and p53 loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2021-05-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2022.05.07.491026v1?rss=1">
<title>
<![CDATA[
A detailed landscape of genomic alterations in malignant peripheral nerve sheath tumor cell lines challenges the current MPNST diagnosis 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2022.05.07.491026v1?rss=1"
</link>
<description><![CDATA[
BackgroundMalignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that arise from the peripheral nervous system. Half of the tumors develop in the context of the genetic disease Neurofibromatosis type 1 (NF1) and the rest are sporadic sarcomas. MPNSTs have a dismal prognosis due to their aggressiveness and tendency to metastasize, and new treatment options are needed. The diagnosis of MPNSTs can be challenging, especially outside of the NF1 context since specific histological criteria have not been completely established. Genomic analysis may both facilitate differential diagnoses and suggest precision medicine strategies.

MethodsWe generated a complete genomic resource of a set of widely used human NF1-related and sporadic MPNST cell lines by applying ploidy analysis, whole genome and whole exome sequencing and SNP-array analysis, complemented by methylome-based classification and immunofluorescence of cell identity markers (SOX9, SOX10, S100B).

ResultsNF1 MPNST cell lines faithfully recapitulated the genomic copy number profile of primary MPNSTs. Structural variants were key players in the complete inactivation of most recurrently altered tumor suppressor genes (TSGs) (NF1, CDKN2A, SUZ12/EED), while small variants played a minor role in the NF1 context, both concerning TSG inactivation and due to the absence of gain-of-function mutations. In clear contrast, the sporadic cell lines (STS-26T, HS-Sch-2, HS-PSS) did not recapitulate the copy number profile of primary MPNSTs. They carried different TSG inactivation and exhibited gain-of-function mutations by predicted kinase activation or generation of fusion genes. Mutational frequencies and signatures emerged as promising informative tools for aiding in MPNST differential diagnosis. Due to the multiple genomic differences exhibited, we complemented their characterization using a methylome-based classifier. All NF1-related cell lines were assigned within the MPNST group, while sporadic cell lines clustered either with melanomas or with an uncertain MPNST-like sarcoma group. The staining of cell identity markers reinforced the idea of a potential misdiagnose of the MPNSTs used to derive the sporadic cell lines analyzed.

ConclusionsDeep genomic analysis, together with methylome-based sarcoma classification and cell identity marker analysis, challenged the MPNST identity of sporadic cell lines. Results presented here open an opportunity to revise MPNST differential diagnosis and classification.
]]></description>
<dc:creator>Magallon-Lorenz, M.</dc:creator>
<dc:creator>Terribas, E.</dc:creator>
<dc:creator>Fernandez, M. A.</dc:creator>
<dc:creator>Requena, G.</dc:creator>
<dc:creator>Rosas, I.</dc:creator>
<dc:creator>Mazuelas, H.</dc:creator>
<dc:creator>Uriarte, I.</dc:creator>
<dc:creator>Negro, A.</dc:creator>
<dc:creator>Castellanos, E.</dc:creator>
<dc:creator>Blanco, I.</dc:creator>
<dc:creator>DeVries, G.</dc:creator>
<dc:creator>Kawashima, H.</dc:creator>
<dc:creator>Legius, E.</dc:creator>
<dc:creator>Brems, H.</dc:creator>
<dc:creator>Mautner, V.</dc:creator>
<dc:creator>Kluwe, L.</dc:creator>
<dc:creator>Ratner, N.</dc:creator>
<dc:creator>Wallace, M. R.</dc:creator>
<dc:creator>Fernandez-Rodriguez, J.</dc:creator>
<dc:creator>Lazaro, C.</dc:creator>
<dc:creator>Fletcher, J.</dc:creator>
<dc:creator>Reuss, D.</dc:creator>
<dc:creator>Carrio, M.</dc:creator>
<dc:creator>Gel, B.</dc:creator>
<dc:creator>Serra, E.</dc:creator>
<dc:date>2022-05-08</dc:date>
<dc:identifier>doi:10.1101/2022.05.07.491026</dc:identifier>
<dc:title><![CDATA[A detailed landscape of genomic alterations in malignant peripheral nerve sheath tumor cell lines challenges the current MPNST diagnosis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2022-05-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/199026v1?rss=1">
<title>
<![CDATA[
Oncogenic RAS-MET signal interactions are modulated by P53 status in NF1-related MPNSTs 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/199026v1?rss=1"
</link>
<description><![CDATA[
We previously reported that cooperative RAS-MET signaling drives disease progression in NF1-related MPNSTs, and that MET inhibition results in downstream inhibition of RAS/MAPK in the context of MET amplification. This study revealed that response to MET inhibition appeared to be modulated by P53 gene status. It is currently unclear how P53 function affects kinome signaling and response to kinase inhibition. Here we utilized genetically engineered mouse models with variable levels of Met and Hgf amplification and differential p53 status (NF1fl/KO;lox-stop-loxMETtg/+;Plp-creERTtg/+; NF1+/KO;p53R172H;Plp-creERTtg/+; and NF1+/KO;Plp-creERTtg/+t). These NF1-MPNST models were used to assess a novel MET/MEK (i.e. RAS-MET) inhibition strategy and investigate the adaptive kinome response to MET and MEK inhibition. We demonstrate that combination MET (capmatinib) and MEK (trametinib) inhibition fully suppresses MET, RAS/MAPK, and PI3K/AKT activation in P53 wild type tumors, whereas P53-mutant tumors demonstrated sustained CRAF, BRAF, and AKT activation in the presence of combined MET and MEK inhibition. Interestingly, trametinib therapy alone strongly activates MET signaling in MET and HGF-amplified tumors regardless of P53 status, an effect that was abrogated by the addition of capmatinib. We conclude that P53 alters RAS-MET signaling interactions that drive therapy resistance in NF1-related MPNSTs.
]]></description>
<dc:creator>Pridgeon, M. G.</dc:creator>
<dc:creator>Tovar, E. A.</dc:creator>
<dc:creator>Essenburg, C. J.</dc:creator>
<dc:creator>Madaj, Z.</dc:creator>
<dc:creator>Boguslawski, E. A.</dc:creator>
<dc:creator>Dischinger, P. S.</dc:creator>
<dc:creator>Peacock, J. D.</dc:creator>
<dc:creator>Maina, F.</dc:creator>
<dc:creator>Dono, R.</dc:creator>
<dc:creator>Winn, M. E.</dc:creator>
<dc:creator>Graveel, C. R.</dc:creator>
<dc:creator>Steensma, M. R.</dc:creator>
<dc:date>2017-10-05</dc:date>
<dc:identifier>doi:10.1101/199026</dc:identifier>
<dc:title><![CDATA[Oncogenic RAS-MET signal interactions are modulated by P53 status in NF1-related MPNSTs]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2017-10-05</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/199000v1?rss=1">
<title>
<![CDATA[
Genomic MET amplification occurs early in NF1-related malignant peripheral nerve sheath tumor (MPNST) progression and is a potent therapeutic target 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/199000v1?rss=1"
</link>
<description><![CDATA[
Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are highly resistant sarcomas that occur in up to 13% of individuals with Neurofibromatosis Type 1 (NF1). Genomic analysis of longitudinally collected tumor samples in a case of MPNST disease progression revealed early hemizygous microdeletions in NF1 and TP53, with concomitant amplifications of MET, HGF, and EGFR. To examine the role of MET in MPNST progression, we developed mice with enhanced MET expression and NF1 ablation (NF1fl/KO;lox-stop-loxMETtg/+;Plp-creERTtg/+; referred to as NF1-MET). NF1-MET mice express a robust MPNST phenotype in the absence of additional mutations. A comparison of NF1-MET MPSNTs with MPNSTs derived from NF1KO/+;p53R172H;Plp-creERTtg/+ (NF1-P53) and NF1KO/+;Plp-creERTtg/+ (NF1) mice revealed unique Met, Ras, and PI3K signaling patterns. To investigate the therapeutic potential of MET inhibition among tumorgrafts derived from the respective MPNST models, we tested the highly selective MET inhibitor, capmatinib. NF1-MET MPNSTs were uniformly sensitive to MET inhibition whereas only a small subset of NF1-P53 and NF1 MPNSTs were inhibited. These results confirm that MET activation is sufficient for Schwann cell dedifferentiation into MPNSTs in the context of NF1 deficiency. RAS-MET signal interactions may be an important driver of MPSNT disease progression.
]]></description>
<dc:creator>Peacock, J. D.</dc:creator>
<dc:creator>Pridgeon, M. G.</dc:creator>
<dc:creator>Tovar, E. A.</dc:creator>
<dc:creator>Essenburg, C. J.</dc:creator>
<dc:creator>Bowman, M. J.</dc:creator>
<dc:creator>Madaj, Z.</dc:creator>
<dc:creator>Koeman, J.</dc:creator>
<dc:creator>Grit, J.</dc:creator>
<dc:creator>Dodd, R. D.</dc:creator>
<dc:creator>Cardona, D. M.</dc:creator>
<dc:creator>Chen, M.</dc:creator>
<dc:creator>Kirsch, D.</dc:creator>
<dc:creator>Maina, F.</dc:creator>
<dc:creator>Dono, R.</dc:creator>
<dc:creator>Winn, M. E.</dc:creator>
<dc:creator>Graveel, C. R.</dc:creator>
<dc:creator>Steensma, M. R.</dc:creator>
<dc:date>2017-10-05</dc:date>
<dc:identifier>doi:10.1101/199000</dc:identifier>
<dc:title><![CDATA[Genomic MET amplification occurs early in NF1-related malignant peripheral nerve sheath tumor (MPNST) progression and is a potent therapeutic target]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2017-10-05</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/495358v1?rss=1">
<title>
<![CDATA[
Sex-dependent differences in pain and sleep in a porcine model of Neurofibromatosis type 1 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/495358v1?rss=1"
</link>
<description><![CDATA[
Neurofibromatosis Type 1 (NF1) is an autosomal dominant genetic disorder resulting from germline mutations in the NF1 gene, which encodes neurofibromin. Patients experience a variety of symptoms, but pain in the context of NF1 remains largely underrecognized. Here, we characterize nociceptive signaling and pain behaviors in a miniswine harboring a disruptive NF1 mutation (exon 42 deletion). We explore these phenotypes in relationship to collapsin response mediator protein 2 (CRMP2), a known interactor of neurofibromin. Mechanistically, we found two previously unknown phosphorylated residues of CRMP2 in NF1+/ex42del pig dorsal root ganglia (DRGs) and replicated increased voltage-gated calcium channel currents in NF1+/ex42del pig DRGs previously described in rodent models of NF1. We present the first characterization of pain-related behaviors in a pig model of NF1, identifying unchanged agitation scores, lower tactile thresholds (allodynia), and decreased response latencies to thermal laser stimulation (hyperalgesia) in the NF1 mutant animals; NF1+/ex42del pigs demonstrated sexually dimorphic behaviors. NF1+/ex42del pigs showed reduced sleep quality and increased resting, two health-related quality of life symptoms found to be comorbid in people with NF1 pain. Finally, we show decreased depolarization-evoked calcium influx in both wildtype and NF1+/ex42del pig DRGs treated with CRMP2 phosphorylation inhibitor (5)-lacosamide. Our data supports use of NF1+/ex42del pigs as an ideal model for studying NF1-associated pain and are a better model for understanding the pathophysiology of NF1 compared to rodents. Moreover, our findings demonstrate that interfering with CRMP2 phosphorylation might be a promising therapeutic strategy for NF1-related pain management.
]]></description>
<dc:creator>Khanna, R.</dc:creator>
<dc:creator>Moutal, A.</dc:creator>
<dc:creator>White, K.</dc:creator>
<dc:creator>Chefdeville, A.</dc:creator>
<dc:creator>Negrao de Assis, P.</dc:creator>
<dc:creator>Cai, S.</dc:creator>
<dc:creator>Swier, V. J.</dc:creator>
<dc:creator>Bellampalli, S. S.</dc:creator>
<dc:creator>Giunta, M. D.</dc:creator>
<dc:creator>Darbro, B. W.</dc:creator>
<dc:creator>Quelle, D. E.</dc:creator>
<dc:creator>Sieren, J. C.</dc:creator>
<dc:creator>Wallace, M. R.</dc:creator>
<dc:creator>Rogers, C. S.</dc:creator>
<dc:creator>Meyerholz, D. K.</dc:creator>
<dc:creator>Weimer, J. M.</dc:creator>
<dc:date>2018-12-20</dc:date>
<dc:identifier>doi:10.1101/495358</dc:identifier>
<dc:title><![CDATA[Sex-dependent differences in pain and sleep in a porcine model of Neurofibromatosis type 1]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2018-12-20</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.02.14.528378v1?rss=1">
<title>
<![CDATA[
Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.02.14.528378v1?rss=1"
</link>
<description><![CDATA[
PINK1 loss-of-function mutations and exposure to mitochondrial toxins are causative for Parkinsons disease (PD) and Parkinsonism, respectively. We demonstrate that pathological -synuclein deposition, the hallmark pathology of idiopathic PD, induces mitochondrial dysfunction and impairs mitophagy, driving accumulation of the PINK1 substrate pS65-Ubiquitin (pUb) in primary neurons and in vivo. We synthesized MTK458, a brain penetrant small molecule that binds to PINK1 and stabilizes an active heterocomplex, thereby increasing mitophagy. MTK458 mediates clearance of -synuclein pathology in PFF seeding models in vitro and in vivo and reduces pUb. We developed an ultrasensitive assay to quantify pUb levels in plasma and observed an increase in pUb in PD subjects that correlates with disease progression, paralleling our observations in PD models. Our combined findings from preclinical PD models and patient biofluids suggest that pharmacological activation of PINK1 is worthy of further study as a therapeutic strategy for disease modification in PD.

HighlightsO_LIDiscovery of a plasma Parkinsons Disease biomarker candidate, pS65-Ubiquitin (pUb)
C_LIO_LIPlasma pUb levels correlate with disease status and progression in PD patients.
C_LIO_LIIdentification of a potent, brain penetrant PINK1 activator, MTK458
C_LIO_LIMTK458 selectively activates PINK1 by stimulating dimerization and stabilization of the PINK1/TOM complex
C_LIO_LIMTK458 drives clearance of -synuclein pathology and normalizes pUb in in vivo Parkinsons models
C_LI
]]></description>
<dc:creator>Chin, R. M.</dc:creator>
<dc:creator>Rakhit, R.</dc:creator>
<dc:creator>Ditsworth, D.</dc:creator>
<dc:creator>Wang, C.</dc:creator>
<dc:creator>Bartholomeus, J.</dc:creator>
<dc:creator>Liu, S.</dc:creator>
<dc:creator>Mody, A.</dc:creator>
<dc:creator>Laihsu, A.</dc:creator>
<dc:creator>Eastes, A.</dc:creator>
<dc:creator>Tai, C.</dc:creator>
<dc:creator>Kim, R.</dc:creator>
<dc:creator>Li, J.</dc:creator>
<dc:creator>Hansberry, S.</dc:creator>
<dc:creator>Khasnavis, S.</dc:creator>
<dc:creator>Rafalski, V.</dc:creator>
<dc:creator>Heerendeen, D.</dc:creator>
<dc:creator>Garda, V.</dc:creator>
<dc:creator>Phung, J.</dc:creator>
<dc:creator>de Roulet, D.</dc:creator>
<dc:creator>Ordureau, A.</dc:creator>
<dc:creator>Harper, J. W.</dc:creator>
<dc:creator>Johnstone, S.</dc:creator>
<dc:creator>Stoehr, J.</dc:creator>
<dc:creator>Hertz, N. T.</dc:creator>
<dc:date>2023-02-15</dc:date>
<dc:identifier>doi:10.1101/2023.02.14.528378</dc:identifier>
<dc:title><![CDATA[Pharmacological PINK1 activation ameliorates Pathology in Parkinson's Disease models]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-02-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.02.10.527867v1?rss=1">
<title>
<![CDATA[
Parallel Neurodegenerative Phenotypes in Sporadic Parkinsons Disease Fibroblasts and Midbrain Dopamine Neurons 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.02.10.527867v1?rss=1"
</link>
<description><![CDATA[
Understanding the mechanisms causing Parkinsons disease (PD) is vital to the development of much needed early diagnostics and therapeutics for this debilitating condition. Here, we report cellular and molecular alterations in skin fibroblasts of late-onset sporadic PD subjects, that were recapitulated in matched induced pluripotent stem cell (iPSC)-derived midbrain dopamine (DA) neurons, reprogrammed from the same fibroblasts. Specific changes in growth, morphology, reactive oxygen species levels, mitochondrial function, and autophagy, were seen in both the PD fibroblasts and DA neurons, as compared to their respective controls. Additionally, significant alterations in alpha synuclein expression and electrical activity were also noted in the PD DA neurons. Interestingly, although the fibroblast and neuronal phenotypes were similar to each other, they also differed in their nature and scale. Furthermore, statistical analysis revealed novel associations between various clinical measures of the PD subjects and the different fibroblast and neuronal data. In essence, these findings encapsulate spontaneous, in-tandem, disease-related phenotypes in both sporadic PD fibroblasts and iPSC-based DA neurons, from the same patient, and generates an innovative model to investigate PD mechanisms with a view towards rational disease stratification and precision treatments.
]]></description>
<dc:creator>Corenblum, M. J.</dc:creator>
<dc:creator>McRobbie-Johnson, A.</dc:creator>
<dc:creator>Carruth, E.</dc:creator>
<dc:creator>Bernard, K.</dc:creator>
<dc:creator>Luo, M.</dc:creator>
<dc:creator>Mandarino, L. J.</dc:creator>
<dc:creator>Peterson, S.</dc:creator>
<dc:creator>Billheimer, D.</dc:creator>
<dc:creator>Maley, T.</dc:creator>
<dc:creator>Eggers, E. D.</dc:creator>
<dc:creator>Madhavan, L.</dc:creator>
<dc:date>2023-02-12</dc:date>
<dc:identifier>doi:10.1101/2023.02.10.527867</dc:identifier>
<dc:title><![CDATA[Parallel Neurodegenerative Phenotypes in Sporadic Parkinsons Disease Fibroblasts and Midbrain Dopamine Neurons]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-02-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.15.537033v1?rss=1">
<title>
<![CDATA[
Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.15.537033v1?rss=1"
</link>
<description><![CDATA[
We developed a flexible "electrode-thread" array for recording dopamine neurochemical activity from a lateral distribution of subcortical targets (up to 16) transverse to the axis of insertion. Ultrathin ([~] 10 {micro}m diameter) carbon fiber (CF) electrode-threads (CFETs) are clustered into a tight bundle to introduce them into the brain from a single entry point. The individual CFETs splay laterally in deep brain tissue during insertion due to their innate flexibility. This spatial redistribution allows navigation of the CFETs towards deep brain targets spreading horizontally from the axis of insertion. Commercial "linear" arrays provide single entry insertion but only allow measurements along the axis of insertion. Horizontally configured neurochemical recording arrays inflict separate penetrations for each individual channel (i.e., electrode). We tested functional performance of our CFET arrays in vivo for recording dopamine neurochemical dynamics and for providing lateral spread to multiple distributed sites in the striatum of rats. Spatial spread was further characterized using agar brain phantoms to measure electrode deflection as a function of insertion depth. We also developed protocols to slice the embedded CFETs within fixed brain tissue using standard histology techniques. This method allowed extraction of the precise spatial coordinates of the implanted CFETs and their recording sites as integrated with immunohistochemical staining for surrounding anatomical, cytological, and protein expression labels. Neurochemical recording operations tested here can be integrated with already widely established capabilities of CF-based electrodes to record single neuron activity and local field potentials, to enable multi-modal recording functions. Our CFET array has the potential to unlock a wide range of applications, from uncovering the role of neuromodulators in synaptic plasticity, to addressing critical safety barriers in clinical translation towards diagnostic and adaptive treatment in Parkinsons disease and major mood disorders.
]]></description>
<dc:creator>Xia, M.</dc:creator>
<dc:creator>Agca, B. N.</dc:creator>
<dc:creator>Yoshida, T.</dc:creator>
<dc:creator>Choi, J.</dc:creator>
<dc:creator>Amjad, U.</dc:creator>
<dc:creator>Bose, K.</dc:creator>
<dc:creator>Keren, N.</dc:creator>
<dc:creator>Zukerman, S.</dc:creator>
<dc:creator>Cima, M. J.</dc:creator>
<dc:creator>Graybiel, A. M.</dc:creator>
<dc:creator>Schwerdt, H. N.</dc:creator>
<dc:date>2023-04-17</dc:date>
<dc:identifier>doi:10.1101/2023.04.15.537033</dc:identifier>
<dc:title><![CDATA[Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.29.534370v1?rss=1">
<title>
<![CDATA[
Splicing accuracy varies across human introns, tissues and age 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.29.534370v1?rss=1"
</link>
<description><![CDATA[
Alternative splicing impacts most multi-exonic human genes. Inaccuracies during this process may have an important role in ageing and disease. Here, we investigated mis-splicing using RNA-sequencing data from ~14K control samples and 42 human body sites, focusing on split reads partially mapping to known transcripts in annotation. We show that mis-splicing occurs at different rates across introns and tissues and that these splicing inaccuracies are primarily affected by the abundance of core components of the spliceosome assembly and its regulators. Using publicly available data on short-hairpin RNA-knockdowns of numerous spliceosomal components and related regulators, we found support for the importance of RNA-binding proteins in mis-splicing. We also demonstrated that age is positively correlated with mis-splicing, and it affects genes implicated in neurodegenerative diseases. This in-depth characterisation of mis-splicing can have important implications for our understanding of the role of splicing inaccuracies in human disease and the interpretation of long-read RNA-sequencing data.
]]></description>
<dc:creator>Garcia-Ruiz, S.</dc:creator>
<dc:creator>Zhang, D.</dc:creator>
<dc:creator>Gustavsson, E. K.</dc:creator>
<dc:creator>Rocamora-Perez, G.</dc:creator>
<dc:creator>Grant-Peters, M.</dc:creator>
<dc:creator>Fairbrother-Browne, A.</dc:creator>
<dc:creator>Reynolds, R. H.</dc:creator>
<dc:creator>Brenton, J. W.</dc:creator>
<dc:creator>Gil-Martinez, A. L.</dc:creator>
<dc:creator>Chen, Z.</dc:creator>
<dc:creator>Rio, D. C.</dc:creator>
<dc:creator>Botia, J. A.</dc:creator>
<dc:creator>Guelfi, S.</dc:creator>
<dc:creator>Collado-Torres, L.</dc:creator>
<dc:creator>Ryten, M.</dc:creator>
<dc:date>2023-03-30</dc:date>
<dc:identifier>doi:10.1101/2023.03.29.534370</dc:identifier>
<dc:title><![CDATA[Splicing accuracy varies across human introns, tissues and age]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.14.532535v1?rss=1">
<title>
<![CDATA[
Lifespan Neurodegeneration Of The Human Brain In Multiple Sclerosis 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.14.532535v1?rss=1"
</link>
<description><![CDATA[
BackgroundAtrophy related to Multiple Sclerosis (MS) has been found at the early stages of the disease. However, the archetype dynamic trajectories of the neurodegenerative process, even prior to clinical diagnosis, remain unknown.

MethodsWe modeled the volumetric trajectories of brain structures across the entire lifespan using 40944 subjects (38295 healthy controls and 2649 MS patients). Then, we estimated the chronological progression of MS by assessing the divergence of lifespan trajectories between normal brain charts and MS brain charts.

ResultsChronologically, the first affected structure was the thalamus, then the putamen and the pallidum (3 years later), followed by the ventral diencephalon (7 years after thalamus) and finally the brainstem (9 years after thalamus). To a lesser extent, the anterior cingulate gyrus, insular cortex, occipital pole, caudate and hippocampus were impacted. Finally, the precuneus and accumbens nuclei exhibited a limited atrophy pattern.

ConclusionSubcortical atrophy was more pronounced than cortical atrophy. The thalamus was the most impacted structure with a very early divergence in life. It paves the way toward utilization of these lifespan models for future preclinical/prodromal prognosis and monitoring of MS.
]]></description>
<dc:creator>Coupe, P.</dc:creator>
<dc:creator>Planche, V.</dc:creator>
<dc:creator>Mansencal, B.</dc:creator>
<dc:creator>Kamraoui, R. A.</dc:creator>
<dc:creator>Koubiyr, I.</dc:creator>
<dc:creator>Manjon, J.</dc:creator>
<dc:creator>Tourdias, T.</dc:creator>
<dc:date>2023-03-14</dc:date>
<dc:identifier>doi:10.1101/2023.03.14.532535</dc:identifier>
<dc:title><![CDATA[Lifespan Neurodegeneration Of The Human Brain In Multiple Sclerosis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-14</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.21.537695v1?rss=1">
<title>
<![CDATA[
hipFG: High-throughput harmonization and integration pipeline for functional genomics data 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.21.537695v1?rss=1"
</link>
<description><![CDATA[
SummaryPreparing functional genomic (FG) data with diverse assay types and file formats for integration into analysis workflows that interpret genome-wide association and other studies is a significant and time-consuming challenge. Here we introduce hipFG, an automatically customized pipeline for efficient and scalable normalization of heterogenous FG data collections into standardized, indexed, rapidly searchable analysis-ready datasets while accounting for FG datatypes (e.g., chromatin interactions, genomic intervals, quantitative trait loci).

Availability and ImplementationhipFG is freely available at https://bitbucket.org/wanglab-upenn/hipFG. Docker container is available at https://hub.docker.com/r/wanglab/hipfg.

Contactlswang@pennmedicine.upenn.edu

Supplementary informationSupplementary data are available as BioRxiv supplemental files.
]]></description>
<dc:creator>Cifello, J.</dc:creator>
<dc:creator>Kuksa, P. P.</dc:creator>
<dc:creator>Saravanan, N.</dc:creator>
<dc:creator>Valladares, O.</dc:creator>
<dc:creator>Leung, Y. Y.</dc:creator>
<dc:creator>Wang, L.-S.</dc:creator>
<dc:date>2023-04-25</dc:date>
<dc:identifier>doi:10.1101/2023.04.21.537695</dc:identifier>
<dc:title><![CDATA[hipFG: High-throughput harmonization and integration pipeline for functional genomics data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.09.523303v1?rss=1">
<title>
<![CDATA[
Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.09.523303v1?rss=1"
</link>
<description><![CDATA[
The defining feature of Parkinson disease (PD) and Lewy body dementia (LBD) is the accumulation of alpha-synuclein (Asyn) fibrils in Lewy bodies and Lewy neurites. We developed and validated a novel method to amplify Asyn fibrils extracted from LBD postmortem tissue samples and used solid state nuclear magnetic resonance (SSNMR) studies to determine atomic resolution structure. Amplified LBD Asyn fibrils comprise two protofilaments with pseudo-21 helical screw symmetry, very low twist and an interface formed by antiparallel beta strands of residues 85-93. The fold is highly similar to the fold determined by a recent cryo-electron microscopy study for a minority population of twisted single protofilament fibrils extracted from LBD tissue. These results expand the structural landscape of LBD Asyn fibrils and inform further studies of disease mechanisms, imaging agents and therapeutics targeting Asyn.
]]></description>
<dc:creator>Dhavale, D. D.</dc:creator>
<dc:creator>Barclay, A. M.</dc:creator>
<dc:creator>Borcik, C. G.</dc:creator>
<dc:creator>Basore, K.</dc:creator>
<dc:creator>Gordon, I. R.</dc:creator>
<dc:creator>Liu, J.</dc:creator>
<dc:creator>Milchberg, M. H.</dc:creator>
<dc:creator>O'Shea, J. Y.</dc:creator>
<dc:creator>Rau, M. J.</dc:creator>
<dc:creator>Smith, Z.</dc:creator>
<dc:creator>Sen, S.</dc:creator>
<dc:creator>Summers, B.</dc:creator>
<dc:creator>Smith, J. W.</dc:creator>
<dc:creator>Warmuth, O. A.</dc:creator>
<dc:creator>Chen, Q.</dc:creator>
<dc:creator>Fitzpatrick, J. A. J.</dc:creator>
<dc:creator>Schwieters, C. D.</dc:creator>
<dc:creator>Tajkhorshid, E.</dc:creator>
<dc:creator>Rienstra, C. M.</dc:creator>
<dc:creator>Kotzbauer, P. T.</dc:creator>
<dc:date>2023-01-10</dc:date>
<dc:identifier>doi:10.1101/2023.01.09.523303</dc:identifier>
<dc:title><![CDATA[Structure of alpha-synuclein fibrils derived from human Lewy body dementia tissue]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.24.525105v1?rss=1">
<title>
<![CDATA[
Nuclease-dead S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in patient-derived stem cell model of Parkinson's disease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.24.525105v1?rss=1"
</link>
<description><![CDATA[
Parkinsons disease (PD) is one of the most common neurodegenerative diseases, but no disease modifying therapies have been successful in clinical translation presenting a major unmet medical need. A promising target is alpha-synuclein or its aggregated form, which accumulates in the brain of PD patients as Lewy bodies. While it is not entirely clear which alpha-synuclein protein species is disease relevant, mere overexpression of alpha-synuclein in hereditary forms leads to neurodegeneration.

To specifically address gene regulation of alpha-synuclein, we developed a CRISPR interference (CRISPRi) system based on the nuclease dead S. aureus Cas9 (SadCas9) fused with the transcriptional repressor domain Krueppel-associated box to controllably repress alpha-synuclein expression at the transcriptional level. We screened single guide (sg)RNAs across the SNCA promoter and identified several sgRNAs that mediate downregulation of alpha-synuclein at varying levels. CRISPRi downregulation of alpha-synuclein in iPSC-derived neuronal cultures from a patient with an SNCA genomic triplication showed functional recovery by reduction of oxidative stress and mitochondrial DNA damage.

Our results are proof-of-concept in vitro for precision medicine by targeting the SNCA gene promoter. The SNCA CRISPRi approach presents a new model to understand safe levels of alpha-synuclein downregulation and a novel therapeutic strategy for PD and related alpha-synucleinopathies.
]]></description>
<dc:creator>Sastre, D.</dc:creator>
<dc:creator>Zafar, F.</dc:creator>
<dc:creator>Torres, C. A. M.</dc:creator>
<dc:creator>Piper, D.</dc:creator>
<dc:creator>Kirik, D.</dc:creator>
<dc:creator>Sanders, L. H.</dc:creator>
<dc:creator>Qi, S.</dc:creator>
<dc:creator>Schuele, B.</dc:creator>
<dc:date>2023-01-24</dc:date>
<dc:identifier>doi:10.1101/2023.01.24.525105</dc:identifier>
<dc:title><![CDATA[Nuclease-dead S. aureus Cas9 downregulates alpha-synuclein and reduces mtDNA damage and oxidative stress levels in patient-derived stem cell model of Parkinson's disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.01.535194v1?rss=1">
<title>
<![CDATA[
Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.01.535194v1?rss=1"
</link>
<description><![CDATA[
Little is known about circular RNAs (circRNAs) in specific brain cells and human neuropsychiatric disease. Here, we systematically identified over 11,039 circRNAs expressed in vulnerable dopamine and pyramidal neurons laser-captured from 190 human brains and non-neuronal cells using ultra-deep, total RNA sequencing. 1,526 and 3,308 circRNAs were custom-tailored to the cell identity of dopamine and pyramidal neurons and enriched in synapse pathways. 88% of Parkinsons and 80% of Alzheimers disease-associated genes produced circRNAs. circDNAJC6, produced from a juvenile-onset Parkinsons gene, was already dysregulated during prodromal, onset stages of common Parkinsons disease neuropathology. Globally, addiction-associated genes preferentially produced circRNAs in dopamine neurons, autism-associated genes in pyramidal neurons, and cancers in non-neuronal cells. This study shows that circular RNAs in the human brain are tailored to neuron identity and implicate circRNA- regulated synaptic specialization in neuropsychiatric diseases.
]]></description>
<dc:creator>Dong, X.</dc:creator>
<dc:creator>Bai, Y.</dc:creator>
<dc:creator>Liao, Z.</dc:creator>
<dc:creator>Gritsch, D.</dc:creator>
<dc:creator>Liu, X.</dc:creator>
<dc:creator>Wang, T.</dc:creator>
<dc:creator>Borges-Monroy, R.</dc:creator>
<dc:creator>Ehrlich, A.</dc:creator>
<dc:creator>Serano, G. E.</dc:creator>
<dc:creator>Feany, M. B.</dc:creator>
<dc:creator>Beach, T. G.</dc:creator>
<dc:creator>Scherzer, C. R.</dc:creator>
<dc:date>2023-04-03</dc:date>
<dc:identifier>doi:10.1101/2023.04.01.535194</dc:identifier>
<dc:title><![CDATA[Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.30.538317v1?rss=1">
<title>
<![CDATA[
The LRRK2 kinase substrates Rab8a and Rab10 contribute complementary but distinct disease-relevant phenotypes in human neurons 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.30.538317v1?rss=1"
</link>
<description><![CDATA[
Mutations in the LRRK2 gene cause familial Parkinsons disease presenting with pleomorphic neuropathology that can involve -synuclein or tau accumulation. LRRK2 mutations are thought to converge toward a pathogenic increase in LRRK2 kinase activity. A subset of small Rab GTPases have been identified as LRRK2 substrates, with LRRK2-dependent phosphorylation resulting in Rab inactivation. We used CRISPR/Cas9 genome editing to generate a novel series of isogenic iPSC lines deficient in the two most well validated LRRK2 substrates, Rab8a and Rab10, from two independent, deeply phenotyped healthy control lines. Thorough characterization of NGN2-induced neurons revealed divergent effects of Rab8a and Rab10 deficiency on lysosomal pH, LAMP1 association with Golgi, -synuclein insolubility and tau phosphorylation, while parallel effects on lysosomal numbers and Golgi clustering were observed. Our data demonstrate largely antagonistic effects of genetic Rab8a or Rab10 inactivation which provide discrete insight into the pathologic features of their biochemical inactivation by pathogenic LRRK2 mutation.

HighlightsO_LIRab8a and Rab10 deficiency induce lysosomal and Golgi defects
C_LIO_LIRab8a and Rab10 deficiency induce opposing effects on lysosomal pH
C_LIO_LIRab8a KO and Rab10 KO neurons show divergent effects on synuclein and tau proteostasis
C_LIO_LIInactivation of different Rab GTPases can induce distinct disease-relevant phenotypes
C_LI
]]></description>
<dc:creator>Mamais, A.</dc:creator>
<dc:creator>Sanyal, A.</dc:creator>
<dc:creator>Fajfer, A.</dc:creator>
<dc:creator>Zykoski, C. G.</dc:creator>
<dc:creator>Guldin, M.</dc:creator>
<dc:creator>Riley-DiPaolo, A.</dc:creator>
<dc:creator>Subrahmanian, N.</dc:creator>
<dc:creator>Gibbs, W. S.</dc:creator>
<dc:creator>Lin, S.</dc:creator>
<dc:creator>LaVoie, M. J.</dc:creator>
<dc:date>2023-04-30</dc:date>
<dc:identifier>doi:10.1101/2023.04.30.538317</dc:identifier>
<dc:title><![CDATA[The LRRK2 kinase substrates Rab8a and Rab10 contribute complementary but distinct disease-relevant phenotypes in human neurons]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-30</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.07.531573v1?rss=1">
<title>
<![CDATA[
O-GlcNAc modification forces the formation of an α-Synuclein amyloid-strain with notably diminished seeding activity and pathology 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.07.531573v1?rss=1"
</link>
<description><![CDATA[
The process of amyloid fibril formation remains one of the primary targets for developing diagnostics and treatments for several neurodegenerative diseases (NDDs). Amyloid-forming proteins such -Synuclein and Tau, which are implicated in the pathogenesis of Alzheimers and Parkinsons disease, can form different types of fibril structure, or strains, that exhibit distinct structures, toxic properties, seeding activities, and pathology spreading patterns in the brain. Therefore, understanding the molecular and structural determinants contributing to the formation of different amyloid strains or their distinct features could open new avenues for developing disease-specific diagnostics and therapies. In this work, we report that O-GlcNAc modification of -Synuclein monomers results in the formation of amyloid fibril with distinct core structure, as revealed by Cryo-EM, and diminished seeding activity in seeding-based neuronal and rodent models of Parkinsons disease. Although the mechanisms underpinning the seeding neutralization activity of the O-GlcNAc modified fibrils remain unclear, our in vitro mechanistic studies indicate that heat shock proteins interactions with O-GlcNAc fibril inhibit their seeding activity, suggesting that the O-GlcNAc modification may alter the interactome of the -Synuclein fibrils in ways that lead to reduce seeding activity in vivo. Our results show that post-translational modifications, such as O-GlcNAc modification, of -Synuclein are key determinants of -Synuclein amyloid strains and pathogenicity. These findings have significant implications for how we investigate and target amyloids in the brain and could possibly explain the lack of correlation between amyloid burden and neurodegeneration or cognitive decline in some subtypes of NDDs.
]]></description>
<dc:creator>Balana, A. T.</dc:creator>
<dc:creator>Mahul-Mellier, A.-L.</dc:creator>
<dc:creator>Nguyen, B. A.</dc:creator>
<dc:creator>Javed, A.</dc:creator>
<dc:creator>Hard, E. R.</dc:creator>
<dc:creator>Jasiqi, Y.</dc:creator>
<dc:creator>Singh, P.</dc:creator>
<dc:creator>Pedretti, R.</dc:creator>
<dc:creator>Singh, V.</dc:creator>
<dc:creator>Lee, V. M.-Y.</dc:creator>
<dc:creator>Luk, K. C.</dc:creator>
<dc:creator>Lashuel, H. R.</dc:creator>
<dc:creator>Pratt, M. R.</dc:creator>
<dc:date>2023-03-07</dc:date>
<dc:identifier>doi:10.1101/2023.03.07.531573</dc:identifier>
<dc:title><![CDATA[O-GlcNAc modification forces the formation of an α-Synuclein amyloid-strain with notably diminished seeding activity and pathology]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-07</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.27.534444v1?rss=1">
<title>
<![CDATA[
Proteostasis and lysosomal quality control deficits in Alzheimer's disease neurons 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.27.534444v1?rss=1"
</link>
<description><![CDATA[
Aging is the most prominent risk factor for Alzheimers disease (AD). However, the cellular mechanisms linking neuronal proteostasis decline to the characteristic aberrant protein deposits in AD brains remain elusive. Here, we develop transdifferentiated neurons (tNeurons) from human dermal fibroblasts as a neuronal model that retains aging hallmarks and exhibits AD-linked vulnerabilities. Remarkably, AD tNeurons accumulate proteotoxic deposits, including phospho-Tau and A{beta}, resembling those in AD patient and APP mouse brains. Quantitative tNeuron proteomics identify aging and AD-linked deficits in proteostasis and organelle homeostasis, most notably in endosome-lysosomal components. Lysosomal deficits in aged tNeurons, including constitutive lysosomal damage and ESCRT-mediated lysosomal repair defects, are exacerbated in AD tNeurons and linked to inflammatory cytokine secretion and cell death. Supporting lysosomal deficits centrality in AD, compounds ameliorating lysosomal function reduce A{beta} deposits and cytokine secretion. Thus, the tNeuron model system reveals impaired lysosomal homeostasis as an early event of aging and AD.
]]></description>
<dc:creator>Chou, C.-C.</dc:creator>
<dc:creator>Vest, R.</dc:creator>
<dc:creator>Prado, M. A.</dc:creator>
<dc:creator>Wilson-Grady, J.</dc:creator>
<dc:creator>Paulo, J. A.</dc:creator>
<dc:creator>Shibuya, Y.</dc:creator>
<dc:creator>Moran-Losada, P.</dc:creator>
<dc:creator>Lee, T.-T.</dc:creator>
<dc:creator>Luo, J.</dc:creator>
<dc:creator>Gygi, S. P.</dc:creator>
<dc:creator>Kelly, J. W.</dc:creator>
<dc:creator>Finley, D.</dc:creator>
<dc:creator>Wernig, M.</dc:creator>
<dc:creator>Wyss-Coray, T.</dc:creator>
<dc:creator>Frydman, J.</dc:creator>
<dc:date>2023-03-27</dc:date>
<dc:identifier>doi:10.1101/2023.03.27.534444</dc:identifier>
<dc:title><![CDATA[Proteostasis and lysosomal quality control deficits in Alzheimer's disease neurons]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-27</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.12.523790v1?rss=1">
<title>
<![CDATA[
Scalable Nanopore sequencing of human genomes provides a comprehensive view of haplotype-resolved variation and methylation 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.12.523790v1?rss=1"
</link>
<description><![CDATA[
Long-read sequencing technologies substantially overcome the limitations of short-reads but to date have not been considered as feasible replacement at scale due to a combination of being too expensive, not scalable enough, or too error-prone. Here, we develop an efficient and scalable wet lab and computational protocol for Oxford Nanopore Technologies (ONT) long-read sequencing that seeks to provide a genuine alternative to short-reads for large-scale genomics projects. We applied our protocol to cell lines and brain tissue samples as part of a pilot project for the NIH Center for Alzheimers and Related Dementias (CARD). Using a single PromethION flow cell, we can detect SNPs with F1-score better than Illumina short-read sequencing. Small indel calling remains difficult within homopolymers and tandem repeats, but is comparable to Illumina calls elsewhere. Further, we can discover structural variants with F1-score comparable to state-of-the-art methods involving Pacific Biosciences HiFi sequencing and trio information (but at a lower cost and greater throughput). Using ONT-based phasing, we can then combine and phase small and structural variants at megabase scales. Our protocol also produces highly accurate, haplotype-specific methylation calls. Overall, this makes large-scale long-read sequencing projects feasible; the protocol is currently being used to sequence thousands of brain-based genomes as a part of the NIH CARD initiative. We provide the protocol and software as open-source integrated pipelines for generating phased variant calls and assemblies.
]]></description>
<dc:creator>Kolmogorov, M.</dc:creator>
<dc:creator>Billingsley, K. J.</dc:creator>
<dc:creator>Mastoras, M.</dc:creator>
<dc:creator>Meredith, M.</dc:creator>
<dc:creator>Monlong, J.</dc:creator>
<dc:creator>Lorig-Roach, R.</dc:creator>
<dc:creator>Asri, M.</dc:creator>
<dc:creator>Alvarez Jerez, P.</dc:creator>
<dc:creator>Malik, L.</dc:creator>
<dc:creator>Dewan, R.</dc:creator>
<dc:creator>Reed, X.</dc:creator>
<dc:creator>Genner, R. M.</dc:creator>
<dc:creator>Daida, K.</dc:creator>
<dc:creator>Behera, S.</dc:creator>
<dc:creator>Shafin, K.</dc:creator>
<dc:creator>Pesout, T.</dc:creator>
<dc:creator>Prabakaran, J.</dc:creator>
<dc:creator>Carnevali, P.</dc:creator>
<dc:creator>North American Brain Expression Consortium (NABEC),</dc:creator>
<dc:creator>Yang, J.</dc:creator>
<dc:creator>Rhie, A.</dc:creator>
<dc:creator>Scholz, S. W.</dc:creator>
<dc:creator>Traynor, B. J.</dc:creator>
<dc:creator>Miga, K. H.</dc:creator>
<dc:creator>Jain, M.</dc:creator>
<dc:creator>Timp, W.</dc:creator>
<dc:creator>Phillippy, A. M.</dc:creator>
<dc:creator>Chaisson, M.</dc:creator>
<dc:creator>Sedlazeck, F. J.</dc:creator>
<dc:creator>Blauwendraat, C.</dc:creator>
<dc:creator>Paten, B.</dc:creator>
<dc:date>2023-01-15</dc:date>
<dc:identifier>doi:10.1101/2023.01.12.523790</dc:identifier>
<dc:title><![CDATA[Scalable Nanopore sequencing of human genomes provides a comprehensive view of haplotype-resolved variation and methylation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.23.525101v1?rss=1">
<title>
<![CDATA[
Neurophysiological signatures of cortical micro-architecture 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.23.525101v1?rss=1"
</link>
<description><![CDATA[
Systematic spatial variation in micro-architecture is observed across the cortex. These micro-architectural gradients are reflected in neural activity, which can be captured by neurophysiological time-series. How spontaneous neurophysiological dynamics are organized across the cortex and how they arise from heterogeneous cortical micro-architecture remains unknown. Here we extensively profile regional neurophysiological dynamics across the human brain by estimating over 6 800 timeseries features from the resting state magnetoencephalography (MEG) signal. We then map regional time-series profiles to a comprehensive multi-modal, multi-scale atlas of cortical micro-architecture, including microstructure, metabolism, neurotransmitter receptors, cell types and laminar differentiation. We find that the dominant axis of neurophysiological dynamics reflects characteristics of power spectrum density and linear correlation structure of the signal, emphasizing the importance of conventional features of electromagnetic dynamics while identifying additional informative features that have traditionally received less attention. Moreover, spatial variation in neurophysiological dynamics is colocalized with multiple micro-architectural features, including genomic gradients, intracortical myelin, neurotransmitter receptors and transporters, and oxygen and glucose metabolism. Collectively, this work opens new avenues for studying the anatomical basis of neural activity.
]]></description>
<dc:creator>Shafiei, G.</dc:creator>
<dc:creator>Fulcher, B. D.</dc:creator>
<dc:creator>Voytek, B.</dc:creator>
<dc:creator>Satterthwaite, T. D.</dc:creator>
<dc:creator>Baillet, S.</dc:creator>
<dc:creator>Misic, B.</dc:creator>
<dc:date>2023-01-23</dc:date>
<dc:identifier>doi:10.1101/2023.01.23.525101</dc:identifier>
<dc:title><![CDATA[Neurophysiological signatures of cortical micro-architecture]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-23</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.29.534819v1?rss=1">
<title>
<![CDATA[
TNF-NFkB-p53 axis restricts in vivo survival of hPSC-derived dopamine neuron 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.29.534819v1?rss=1"
</link>
<description><![CDATA[
Ongoing, first-in-human clinical trials illustrate the feasibility and translational potential of human pluripotent stem cell (hPSC)-based cell therapies in Parkinsons disease (PD). However, a major unresolved challenge in the field is the extensive cell death following transplantation with <10% of grafted dopamine neurons surviving. Here, we performed a pooled CRISPR/Cas9 screen to enhance survival of postmitotic dopamine neurons in vivo. We identified p53-mediated apoptotic cell death as major contributor to dopamine neuron loss and uncovered a causal link of TNFa-NF{kappa}B signaling in limiting cell survival. As a translationally applicable strategy to purify postmitotic dopamine neurons, we performed a cell surface marker screen that enabled purification without the need for genetic reporters. Combining cell sorting with adalimumab pretreatment, a clinically approved and widely used TNFa inhibitor, enabled efficient engraftment of postmitotic dopamine neurons leading to extensive re-innervation and functional recovery in a preclinical PD mouse model. Thus, transient TNFa inhibition presents a clinically relevant strategy to enhance survival and enable engraftment of postmitotic human PSC-derived dopamine neurons in PD.

HighlightsO_LIIn vivo CRISPR-Cas9 screen identifies p53 limiting survival of grafted human dopamine neurons.
C_LIO_LITNF-NF{kappa}B pathway mediates p53-dependent human dopamine neuron death
C_LIO_LICell surface marker screen to enrich human dopamine neurons for translational use.
C_LIO_LIFDA approved TNF-alpha inhibitor rescues in vivo dopamine neuron survival with in vivo function.
C_LI
]]></description>
<dc:creator>Kim, T. W.</dc:creator>
<dc:creator>Koo, S. Y.</dc:creator>
<dc:creator>Riessland, M.</dc:creator>
<dc:creator>Cho, H.</dc:creator>
<dc:creator>Chaudhry, F.</dc:creator>
<dc:creator>Kolisnyk, B.</dc:creator>
<dc:creator>Russo, M. V.</dc:creator>
<dc:creator>Saurat, N.</dc:creator>
<dc:creator>Mehta, S.</dc:creator>
<dc:creator>Garippa, R.</dc:creator>
<dc:creator>Betel, D.</dc:creator>
<dc:creator>Studer, L.</dc:creator>
<dc:date>2023-03-31</dc:date>
<dc:identifier>doi:10.1101/2023.03.29.534819</dc:identifier>
<dc:title><![CDATA[TNF-NFkB-p53 axis restricts in vivo survival of hPSC-derived dopamine neuron]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-31</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.16.532981v1?rss=1">
<title>
<![CDATA[
Transitions between cognitive topographies: contributions of network structure, neuromodulation, and disease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.16.532981v1?rss=1"
</link>
<description><![CDATA[
Patterns of neural activity underlie human cognition. Transitions between these patterns are orchestrated by the brains network architecture. What are the mechanisms linking network structure to cognitively relevant activation patterns? Here we implement principles of network control to investigate how the architecture of the human connectome shapes transitions between 123 experimentally defined cognitive activation maps (cognitive topographies) from the NeuroSynth meta-analytic engine. We also systematically incorporate neurotransmitter receptor density maps (18 receptors and transporters) and disease-related cortical abnormality maps (11 neurodegenerative, psychiatric and neurodevelopmental diseases; N = 17 000 patients, N = 22 000 controls). Integrating large-scale multimodal neuroimaging data from functional MRI, diffusion tractography, cortical morphometry, and positron emission tomography, we simulate how anatomically-guided transitions between cognitive states can be reshaped by pharmacological or pathological perturbation. Our results provide a comprehensive look-up table charting how brain network organisation and chemoarchitecture interact to manifest different cognitive topographies. This computational framework establishes a principled foundation for systematically identifying novel ways to promote selective transitions between desired cognitive topographies.
]]></description>
<dc:creator>Luppi, A. I.</dc:creator>
<dc:creator>Singleton, S. P. I.</dc:creator>
<dc:creator>Hansen, J. Y.</dc:creator>
<dc:creator>Bzdok, D.</dc:creator>
<dc:creator>Kuceyeski, A.</dc:creator>
<dc:creator>Betzel, R.</dc:creator>
<dc:creator>Misic, B.</dc:creator>
<dc:date>2023-03-17</dc:date>
<dc:identifier>doi:10.1101/2023.03.16.532981</dc:identifier>
<dc:title><![CDATA[Transitions between cognitive topographies: contributions of network structure, neuromodulation, and disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.28.538525v1?rss=1">
<title>
<![CDATA[
Prospective role of PAK6 and 14-3-3 gamma as biomarkers for Parkinson's disease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.28.538525v1?rss=1"
</link>
<description><![CDATA[
2.BackgroundParkinsons disease is a progressive neurodegenerative disorder mainly distinguished by sporadic aetiology, although a genetic component is also well established. Variants in the LRRK2 gene are associated with both familiar and sporadic disease. We have previously shown that PAK6 and 14-3-3{gamma} protein interact with and regulate the activity of LRRK2.

ObjectivesThe aim of this study is to quantify PAK6 and 14-3-3{gamma} in plasma as a reliable biomarker strategy for the diagnosis of both sporadic and LRRK2-linked Parkinsons disease.

MethodsAfter an initial quantification of PAK6 and 14-3-3{gamma} expression by means of Western blot in post-mortem human brains, we verified the presence of the two proteins in plasma by using quantitative ELISA tests. We analysed samples obtained from 39 healthy subjects, 40 patients with sporadic Parkinsons disease, 50 LRRK2-G2019S non-manifesting carriers and 31 patients with LRRK2-G2019S Parkinsons disease.

ResultsThe amount of PAK6 and 14-3-3{gamma} is significantly different in patients with Parkinsons disease compared to healthy subjects. Moreover, the amount of PAK6 also varies with the presence of the G2019S mutation in the LRRK2 gene. Although the generalized linear models show a low association between the presence of PD and PAK6, the kinase can be added in a broader panel of biomarkers for the diagnosis of Parkinsons disease.

ConclusionsChanges of PAK6 and 14-3-3{gamma} amount in plasma represent a shared readout for patients affected by sporadic and LRRK2-linked Parkinsons disease. Overall, they can contribute to the establishment of an extended panel of biomarkers for the diagnosis of Parkinsons disease.
]]></description>
<dc:creator>Giusto, E.</dc:creator>
<dc:creator>Maistrello, L.</dc:creator>
<dc:creator>Iannotta, L.</dc:creator>
<dc:creator>Giusti, V.</dc:creator>
<dc:creator>Iovino, L.</dc:creator>
<dc:creator>Bandopadhyay, R.</dc:creator>
<dc:creator>Antonini, A.</dc:creator>
<dc:creator>Bubacco, L.</dc:creator>
<dc:creator>Barresi, R.</dc:creator>
<dc:creator>Plotegher, N.</dc:creator>
<dc:creator>Greggio, E.</dc:creator>
<dc:creator>Civiero, L.</dc:creator>
<dc:date>2023-04-28</dc:date>
<dc:identifier>doi:10.1101/2023.04.28.538525</dc:identifier>
<dc:title><![CDATA[Prospective role of PAK6 and 14-3-3 gamma as biomarkers for Parkinson's disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-28</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.02.27.530238v1?rss=1">
<title>
<![CDATA[
From Policy to Practice: Tracking an Open Science Funding Initiative 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.02.27.530238v1?rss=1"
</link>
<description><![CDATA[
This is a critical moment in the open science landscape. Over the past few years there has been growing momentum to improve open research policies and require grantees to share all research outputs, from datasets to code to protocols, in FAIR (findable, accessible, interoperable and reusable [FAIR]) repositories with persistent identifiers attached. The Aligning Science Across Parkinsons (ASAP) initiative has made substantial investments in improving open science compliance monitoring for its grantees, requiring grantees to update their manuscripts if not all research outputs have been linked in the initial manuscript version. Here, we evaluate ASAPs effectiveness in improving research output sharing for all articles processed through the ASAP compliance workflow between March 1, 2022, and October 1, 2022. Our ultimate goal in sharing our findings is to assist other funders and institutions as they consider open science implementation. By normalizing the open science and compliance process across funding bodies, we hope to simplify and streamline researcher, institutional, and funder workflows, allowing researchers to focus on science by easily leveraging resources and building upon the work of others.
]]></description>
<dc:creator>Ratan, K.</dc:creator>
<dc:creator>McIntosh, S.</dc:creator>
<dc:creator>Shah, H. V.</dc:creator>
<dc:creator>Lewis, M.</dc:creator>
<dc:creator>Dumanis, S. B.</dc:creator>
<dc:creator>Vines, T. H.</dc:creator>
<dc:creator>Schekman, R.</dc:creator>
<dc:creator>Riley, E. A. U.</dc:creator>
<dc:date>2023-02-28</dc:date>
<dc:identifier>doi:10.1101/2023.02.27.530238</dc:identifier>
<dc:title><![CDATA[From Policy to Practice: Tracking an Open Science Funding Initiative]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-02-28</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.27.524249v1?rss=1">
<title>
<![CDATA[
Protein network analysis links the NSL complex to Parkinson's disease and mitochondrial biology 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.27.524249v1?rss=1"
</link>
<description><![CDATA[
Whilst the majority of PD cases are sporadic, much of our understanding of the pathophysiological basis of disease can be traced back to the study of rare, monogenic forms of disease. In the past decade, the availability of Genome-Wide Association Studies (GWAS) has facilitated a shift in focus, toward identifying common risk variants conferring increased risk of developing PD across the population. A recent mitophagy screening assay of GWAS candidates has functionally implicated the non-specific lethal (NSL) complex in the regulation of PINK1-mitophagy. Here, a bioinformatics approach has been taken to investigate the proteome of the NSL complex, to unpick its relevance to PD progression. The mitochondrial NSL interactome has been built, mining 3 separate repositories: PINOT, HIPPIE and MIST, for curated, literature-derived protein-protein interaction (PPI) data. We built; i) the  mitochondrial interactome, applying gene-set enrichment analysis (GSEA) to explore the relevance of the NSL mitochondrial interactome to PD and, ii) the PD-oriented interactome to uncover biological pathways underpinning the NSL /PD association. In this study, we find the mitochondrial NSL interactome to be significantly enriched for the protein products of PD associated genes, including the Mendelian PD genes LRRK2 and VPS35. Additionally, the PD associated interactome is enriched for mitochondrial processes; "mitochondrial cell death", "mitochondrial protein localisation", "membrane protein localisation" and "mitochondrial transport". Our data points to NSL complex members OGT and WDR5 as key drivers of this increased PD association. These findings strengthen a role for mitochondrial quality control in both familial and sporadic disease.
]]></description>
<dc:creator>Kelly, K.</dc:creator>
<dc:creator>Lewis, P.</dc:creator>
<dc:creator>Plun-Favreau, H.</dc:creator>
<dc:creator>Manzoni, C.</dc:creator>
<dc:date>2023-01-27</dc:date>
<dc:identifier>doi:10.1101/2023.01.27.524249</dc:identifier>
<dc:title><![CDATA[Protein network analysis links the NSL complex to Parkinson's disease and mitochondrial biology]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-27</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.09.523202v1?rss=1">
<title>
<![CDATA[
Simultaneous Determination of Size and Shape of Single alpha-Synuclein Oligomers in Solution 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.09.523202v1?rss=1"
</link>
<description><![CDATA[
Soluble oligomers of amyloid-forming proteins are implicated as toxic species in the context of several neurodegenerative diseases. Since the size and shape of these oligomers influences their toxicity, their biophysical characterization is essential for a better understanding of the structure-toxicity relationship. Amyloid oligomers are difficult to characterize by conventional approaches due to their heterogeneity in size and shape, their dynamic aggregation process, and their low abundance. This paper demonstrates that resistive-pulse measurements using polymer-coated solid-state nanopores enable single-particle level characterization of the size and shape of individual Syn oligomers in solution within minutes. A comparison of the resulting size distribution with single-particle analysis by transmission electron microscopy and mass photometry reveals that nanopore-based characterization agrees well with both methods, while providing better size resolution and elucidating that Syn samples are composed of stable oligomer sub-populations that contain multiples of approximately 12 monomers (i.e., 12-, 24-, 48-, 60-, 84-mers). Applying the unique capability of nanopores to approximate particle size and shape to picomolar concentrations of Syn oligomers in the putatively toxic size range, revealed shapes that agree well with previous estimates by cryo-EM with the added advantage that nanopore-based analysis occurs rapidly, in solution, and has the potential to become a widely accessible technique.
]]></description>
<dc:creator>Awasthi, S.</dc:creator>
<dc:creator>Ying, C.</dc:creator>
<dc:creator>Li, J.</dc:creator>
<dc:creator>Mayer, M.</dc:creator>
<dc:date>2023-01-09</dc:date>
<dc:identifier>doi:10.1101/2023.01.09.523202</dc:identifier>
<dc:title><![CDATA[Simultaneous Determination of Size and Shape of Single alpha-Synuclein Oligomers in Solution]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.11.536367v1?rss=1">
<title>
<![CDATA[
A potential patient stratification biomarker for Parkinson's disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.11.536367v1?rss=1"
</link>
<description><![CDATA[
Parkinsos disease (PD) is a common neurodegenerative movement disorder and leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for disease intervention. However, the ability to stratify patients who will benefit from such treatment modalities based on shared etiology is critical for the success of disease-modifying therapies. Ciliary and centrosomal alterations are commonly associated with pathogenic LRRK2 kinase activity and can be detected in many cell types. We previously found centrosomal deficits in immortalized lymphocytes from G2019S-LRRK2 PD patients. Here, to investigate whether such deficits may serve as a potential blood biomarker for PD which is susceptible to LRKK2 inhibitor treatment, we characterized patient-derived cells from distinct PD cohorts. We report centrosomal alterations in peripheral cells from a subset of early-stage idiopathic PD patients which is mitigated by LRRK2 kinase inhibition, supporting a role for aberrant LRRK2 activity in idiopathic PD. Centrosomal defects are detected in R1441G-LRRK2 and G2019S-LRRK2 PD patients and in non-manifesting LRRK2 mutation carriers, indicating that they acumulate prior to a clinical PD diagnosis. They are present in immortalized cells as well as in primary lymphocytes from peripheral blood. These findings indicate that analysis of centrosomal defects as a blood-based patient stratification biomarker may help nominate PD patients who will benefit from LRRK2-related therapeutics.

One-sentence summaryPeripheral blood-derived cells can be employed to stratify Parkinsos disease patients most likely to respond to LRRK2-related therapeutics.
]]></description>
<dc:creator>Naaldijk, Y.</dc:creator>
<dc:creator>Fernandez, B.</dc:creator>
<dc:creator>Fasiczka, R.</dc:creator>
<dc:creator>Fdez, E.</dc:creator>
<dc:creator>Leghay, C.</dc:creator>
<dc:creator>Croitoru, I.</dc:creator>
<dc:creator>Kwok, J. B.</dc:creator>
<dc:creator>Boulesnane, Y.</dc:creator>
<dc:creator>Vizeneux, A.</dc:creator>
<dc:creator>Mutez, E.</dc:creator>
<dc:creator>Calvez, C.</dc:creator>
<dc:creator>Destee, A.</dc:creator>
<dc:creator>Taymans, J.-M.</dc:creator>
<dc:creator>Vinagre Aragon, A.</dc:creator>
<dc:creator>Bergareche Yarza, A.</dc:creator>
<dc:creator>Padmanabhan, S.</dc:creator>
<dc:creator>Delgado, M.</dc:creator>
<dc:creator>Alcalay, R. N.</dc:creator>
<dc:creator>Chatterton, Z.</dc:creator>
<dc:creator>Dzamko, N.</dc:creator>
<dc:creator>Halliday, G.</dc:creator>
<dc:creator>Ruiz-Martinez, J.</dc:creator>
<dc:creator>Chartier-Harlin, M.-C.</dc:creator>
<dc:creator>Hilfiker, S.</dc:creator>
<dc:date>2023-04-12</dc:date>
<dc:identifier>doi:10.1101/2023.04.11.536367</dc:identifier>
<dc:title><![CDATA[A potential patient stratification biomarker for Parkinson's disease based on LRRK2 kinase-mediated centrosomal alterations in peripheral blood-derived cells]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-12</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.31.534916v1?rss=1">
<title>
<![CDATA[
Regulation of Human PINK1 ubiquitin kinase by Serine167, Serine228 and Cysteine412 phosphorylation 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.31.534916v1?rss=1"
</link>
<description><![CDATA[
Loss-of-function mutations in the human PINK1 kinase (hPINK1) are causative of early-onset Parkinsons disease (PD). Activation of hPINK1 induces phosphorylated ubiquitin to initiate removal of damaged mitochondria by autophagy. Previously we solved the structure of the insect PINK1 orthologue, Tribolium castaneum PINK1, and showed that autophosphorylation of Ser205 was critical for ubiquitin interaction and phosphorylation (Kumar, Tamjar, Waddell et al., 2017). In this advance, we report new findings on the regulation of hPINK1 by phosphorylation. We reconstitute E. coli expressed hPINK1 activity in vitro by direct incorporation of phosphoserine at the equivalent site Serine 228 (pSer228), providing direct evidence for a role for Ser228 phosphorylation in hPINK1 activation. Furthermore, using mass spectrometry, we identify six novel Ser/Thr autophosphorylation sites including regulatory Serine167 phosphorylation (pSer167), which in addition to pSer228 is required for ubiquitin recognition and phosphorylation. Strikingly, we also detect phosphorylation of a conserved Cysteine412 (pCys412) residue in the hPINK1 activation segment. Structural modelling suggests that pCys412 inhibits ubiquitin recognition and we demonstrate that mutation of Cys412 to Ala renders hPINK1 more active towards ubiquitin when expressed in human cells. These results outline new insights into hPINK1 activation by pSer167 and pSer228 and a novel inhibitory mechanism mediated by pCys412. These findings will aid in the development of small molecule activators of hPINK1.
]]></description>
<dc:creator>Waddell, A.</dc:creator>
<dc:creator>Ojha, H.</dc:creator>
<dc:creator>Agarwal, S.</dc:creator>
<dc:creator>Clarke, C.</dc:creator>
<dc:creator>Terriente-Felix, A.</dc:creator>
<dc:creator>Zhou, H.</dc:creator>
<dc:creator>Kakade, P.</dc:creator>
<dc:creator>Knebel, A.</dc:creator>
<dc:creator>Shaw, A.</dc:creator>
<dc:creator>Gourlay, R.</dc:creator>
<dc:creator>Varghese, J.</dc:creator>
<dc:creator>Soares, R.</dc:creator>
<dc:creator>Toth, R.</dc:creator>
<dc:creator>Macartney, T.</dc:creator>
<dc:creator>Eyers, P.</dc:creator>
<dc:creator>Morrice, N.</dc:creator>
<dc:creator>Bayliss, R.</dc:creator>
<dc:creator>Whitworth, A. J.</dc:creator>
<dc:creator>Eyers, C.</dc:creator>
<dc:creator>Muqit, M.</dc:creator>
<dc:date>2023-04-01</dc:date>
<dc:identifier>doi:10.1101/2023.03.31.534916</dc:identifier>
<dc:title><![CDATA[Regulation of Human PINK1 ubiquitin kinase by Serine167, Serine228 and Cysteine412 phosphorylation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.01.530578v1?rss=1">
<title>
<![CDATA[
Investigation of Volatile Metabolites in Sebum as Prodromal Indicators of Parkinson's Disease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.01.530578v1?rss=1"
</link>
<description><![CDATA[
Parkinsons Disease (PD) has been associated with a distinct odour, which emanates from the skin and is strongest in sebum-rich areas. In this study, sebum was sampled from participants using cotton gauze and the volatile components emanating from these swabs were analysed directly with thermal desorption gas chromatography - mass spectrometry (TD GC-MS). We analysed subjects with clinically established PD (n=46) along with healthy controls (n=28) sampled from two sites. The volatilome profiles obtained for PD and control cohorts were compared with the profile of participants (n=9) with isolated REM sleep behaviour disorder (iRBD) to investigate metabolite changes in probable prodromal PD. We also compared PD participants sampled at yearly intervals for a total of three years. Volatile compounds from TD GC-MS analysis were found in different quantities between PD, control and iRBD subjects. We found 55 significant features where abundance in samples from individuals with iRBD was intermediate between that found for PD and control samples. Significant features were found to be alkanes and fatty acid methyl esters (FAMEs), with other metabolites identified as an aldehyde, purine and tropinone. In olfactory analysis of the iRBD samples three out of nine were classified PD, and on clinical follow up two of these showed PD symptoms. Further, when analysing the volatilome from longitudinal PD sampling, almost two-thirds of the significant features showed differential regulation over the three visits. Our findings support the use of sebum as an accessible biofluid rich with measurable volatile compounds which alter in abundance in individuals with PD and iRBD, as the disease progresses.
]]></description>
<dc:creator>Walton-Doyle, C.</dc:creator>
<dc:creator>Heim, B.</dc:creator>
<dc:creator>Sinclair, E.</dc:creator>
<dc:creator>Hollywood, K.</dc:creator>
<dc:creator>Milne, J.</dc:creator>
<dc:creator>Holzknecht, E.</dc:creator>
<dc:creator>Stefani, A.</dc:creator>
<dc:creator>Hogl, B.</dc:creator>
<dc:creator>Seppi, K.</dc:creator>
<dc:creator>Silverdale, M.</dc:creator>
<dc:creator>Poewe, W.</dc:creator>
<dc:creator>Barran, P.</dc:creator>
<dc:creator>Trivedi, D. K.</dc:creator>
<dc:date>2023-03-02</dc:date>
<dc:identifier>doi:10.1101/2023.03.01.530578</dc:identifier>
<dc:title><![CDATA[Investigation of Volatile Metabolites in Sebum as Prodromal Indicators of Parkinson's Disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.20.533516v1?rss=1">
<title>
<![CDATA[
Genetic screening identifies integrated stress response kinase HRI (EIF2AK1) as a negative regulator of PINK1 and mitophagy signalling 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.20.533516v1?rss=1"
</link>
<description><![CDATA[
Loss-of-function mutations of the PINK1 kinase cause familial early-onset Parkinsons disease (PD). PINK1 is activated upon mitochondrial damage to phosphorylate Ubiquitin and Parkin to trigger removal of damaged mitochondria by autophagy (mitophagy). PINK1 also indirectly phosphorylates a subset of Rab GTPases including Rab8A. We have performed an siRNA screen targeting all human Ser/Thr kinases in HeLa cells and discovered that knockdown of the eukaryotic translation initiation factor 2-alpha kinase 1 (EIF2AK1), also known as heme-regulated inhibitor (HRI) kinase, a branch of the integrated stress response (ISR), selectively enhances mitochondrial depolarization-induced stabilization of PINK1 and increased phosphorylation of ubiquitin and Rab8A. We confirm our findings in multiple human cell lines, including SK-OV-3, U2OS and ARPE-19 cells. Knockdown of the upstream mitochondrial-cytosol relay component, DELE1, enhanced PINK1 stabilisation and activation similar to EIF2AK1 knockdown. Strikingly, we demonstrate that the small molecule ISR inhibitor, ISRIB, also enhances PINK1 activation and signaling under conditions of mitochondrial damage. Using the mito-QC mitophagy reporter in human cells, we observe that EIF2AK1 knockdown or ISRIB treatment significantly enhances PINK1-dependent mitophagy but does not alter deferiprone-induced mitophagy. Our findings indicate that the DELE1-EIF2AK1 ISR signaling relay is a negative regulator of PINK1-dependent mitophagy and suggest that inhibitors of DELE1-EIF2AK1 and/or ISRIB analogues could have therapeutic benefits in PD and related disorders.
]]></description>
<dc:creator>Singh, P.</dc:creator>
<dc:creator>Volpi, I.</dc:creator>
<dc:creator>Agarwal, S.</dc:creator>
<dc:creator>Wilhelm, L. P.</dc:creator>
<dc:creator>Becchi, G.</dc:creator>
<dc:creator>Macartney, T.</dc:creator>
<dc:creator>Toth, R.</dc:creator>
<dc:creator>Rousseau, A.</dc:creator>
<dc:creator>Masson, G.</dc:creator>
<dc:creator>Ganley, I. G.</dc:creator>
<dc:creator>Muqit, M. M. K.</dc:creator>
<dc:date>2023-03-22</dc:date>
<dc:identifier>doi:10.1101/2023.03.20.533516</dc:identifier>
<dc:title><![CDATA[Genetic screening identifies integrated stress response kinase HRI (EIF2AK1) as a negative regulator of PINK1 and mitophagy signalling]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-22</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.02.535274v1?rss=1">
<title>
<![CDATA[
α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.02.535274v1?rss=1"
</link>
<description><![CDATA[
BackgroundCaudo-rostral migration of pathological forms of -synuclein from the gut to the brain is proposed as an early feature in Parkinson disease (PD) pathogenesis, but the underlying mechanisms remain unknown. Intestinal enteroendocrine cells sense and respond to numerous luminal signals, including bacterial factors, and transmit this information to the brain via the enteric nervous system and vagus nerve. There is evidence that gut bacteria composition and their metabolites change in PD patients and these alterations can trigger -synuclein pathology in animal models.

ObjectiveHere we investigated the effect of toll-like receptor (TLR) and free fatty acid receptor (FFA2/3) agonists on -synuclein levels in mouse STC-1 enteroendocrine cells.

MethodsSTC-1 cells were treated with TLR and FFA2/3 agonists alone and in combination with selective antagonists. The level of -synuclein protein was measured in cell lysates and cell culture media by western blot and ELISA. And the level of -synuclein and tumour necrosis factor (TNF) mRNA was measured by quantitative RT-PCR.

ResultsTLR and FFA receptor agonists significantly increased intracellular and extracellular -synuclein levels and antagonists significantly reduced these effects. TLR and FFA receptor agonists also significantly increased TNF transcription and this was inhibited by corresponding antagonists.

ConclusionsElevated intracellular -synuclein increases the likelihood of aggregation and conversion to toxic forms. Factors derived from bacteria induce -synuclein accumulation in STC-1 cells. Here we provide support for a mechanism by which exposure of enteroendocrine cells to specific bacterial factors found in PD gut dysbiosis might facilitate accumulation and transmission of -synuclein pathology from the gut to the brain.
]]></description>
<dc:creator>Hurley, M. J.</dc:creator>
<dc:creator>Menozzi, E.</dc:creator>
<dc:creator>Koletsi, S.</dc:creator>
<dc:creator>Bates, R.</dc:creator>
<dc:creator>Gegg, M. E.</dc:creator>
<dc:creator>Chau, K.-Y.</dc:creator>
<dc:creator>Blottiere, H. M.</dc:creator>
<dc:creator>Macnaughtan, J.</dc:creator>
<dc:creator>Schapira, A. H. V.</dc:creator>
<dc:date>2023-04-02</dc:date>
<dc:identifier>doi:10.1101/2023.04.02.535274</dc:identifier>
<dc:title><![CDATA[α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.28.538743v1?rss=1">
<title>
<![CDATA[
Longitudinal brain structure changes in Parkinson's disease: a replication study 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.28.538743v1?rss=1"
</link>
<description><![CDATA[
ContextAn existing major challenge in Parkinsons disease (PD) research is the identification of biomarkers of disease progression. While Magnetic Resonance Imaging (MRI) is a potential source of PD biomarkers, none of the MRI measures of PD are robust enough to warrant their adoption in clinical research. This study is part of a project that aims to replicate 11 PD studies reviewed in a recent survey (JAMA neurology, 78(10) 2021) to investigate the robustness of PD neuroimaging findings to data and analytical variations.

ObjectiveThis study attempts to replicate the results in Hanganu et al. (Brain, 137(4) 2014) using data from the Parkinsons Progression Markers Initiative (PPMI).

MethodsUsing 25 PD subjects and 18 healthy controls, we analyzed the rate of change of cortical thickness and of the volume of subcortical structures, and we measured the relationship between MRI structural changes and cognitive decline. We compared our findings to the results in the original study.

ResultsSimilarly to the original study, PD patients with mild cognitive impairment (MCI) exhibited increased cortical thinning over time compared to patients without MCI in the right middle temporal gyrus, insula, and precuneus. (2) The rate of cortical thinning in the left inferior temporal and precentral gyri in PD patients correlated with the change in cognitive performance. (3) There were no group differences in the change of subcortical volumes. (4) We did not find a relationship between the change in subcortical volumes and the change in cognitive performance.

ConclusionDespite important differences in the dataset used in this replication study, and despite differences in sample size, we were able to partially replicate the original results. We produced a publicly available reproducible notebook allowing researchers to further investigate the reproducibility of the results in Hanganu et al. (2014) when more data becomes available in PPMI.
]]></description>
<dc:creator>Sokolowski, A.</dc:creator>
<dc:creator>Bhagwat, N.</dc:creator>
<dc:creator>Chatelain, Y.</dc:creator>
<dc:creator>Dugre, M.</dc:creator>
<dc:creator>Hanganu, A.</dc:creator>
<dc:creator>Monchi, O.</dc:creator>
<dc:creator>McPherson, B.</dc:creator>
<dc:creator>Wang, M.</dc:creator>
<dc:creator>Poline, J.-B.</dc:creator>
<dc:creator>Sharp, M.</dc:creator>
<dc:creator>Glatard, T.</dc:creator>
<dc:date>2023-04-29</dc:date>
<dc:identifier>doi:10.1101/2023.04.28.538743</dc:identifier>
<dc:title><![CDATA[Longitudinal brain structure changes in Parkinson's disease: a replication study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-29</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.09.536178v1?rss=1">
<title>
<![CDATA[
Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.09.536178v1?rss=1"
</link>
<description><![CDATA[
Astrocytes are highly complex cells that mediate critical roles in synapse formation and maintenance by establishing thousands of direct contacts with synapses through their perisynaptic processes. Here, we found that the most common Parkinsonism gene mutation, LRRK2 G2019S, enhances the phosphorylation of the ERM proteins (Ezrin, Radixin, and Moesin), components of the perisynaptic astrocyte processes in a subset of cortical astrocytes. The ERM hyperphosphorylation was accompanied by decreased astrocyte morphological complexity and reduced excitatory synapse density and function. Dampening ERM phosphorylation levels in LRRK2 G2019S mouse astrocytes restored both their morphology and the excitatory synapse density in the anterior cingulate cortex. To determine how LRRK2 mutation impacts Ezrin interactome, we used an in vivo BioID proteomic approach, and we found that astrocytic Ezrin interacts with Atg7, a master regulator of autophagy. The Ezrin/Atg7 interaction is inhibited by Ezrin phosphorylation, thus diminished in LRRK2 G2019S astrocytes. Importantly, the Atg7 function is required to maintain proper astrocyte morphology. Our data provide a molecular pathway through which the LRRK2 G2019S mutation alters astrocyte morphology and synaptic density in a brain-region-specific manner.
]]></description>
<dc:creator>Wang, S.</dc:creator>
<dc:creator>Sivadasan Bindu, D.</dc:creator>
<dc:creator>Tan, C. X.</dc:creator>
<dc:creator>Sakers, K.</dc:creator>
<dc:creator>Takano, T.</dc:creator>
<dc:creator>Rodriguez Salazar, M. P.</dc:creator>
<dc:creator>Dimond, K.</dc:creator>
<dc:creator>Soderling, S. H.</dc:creator>
<dc:creator>La Spada, A. R.</dc:creator>
<dc:creator>Eroglu, C.</dc:creator>
<dc:date>2023-04-10</dc:date>
<dc:identifier>doi:10.1101/2023.04.09.536178</dc:identifier>
<dc:title><![CDATA[Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-10</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.06.521264v1?rss=1">
<title>
<![CDATA[
Diverging Parkinson's Disease Pathology between GBAN370S ,LRRK2G2019S and engineered SNCAA53T iPSC-derived Dopaminergic Neurons 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.06.521264v1?rss=1"
</link>
<description><![CDATA[
Multiple neurodegenerative disorders, including Parkinsons disease (PD) and Alzheimers disease-associated dementia (ADAD), are linked with dopaminergic (DA) neuron death and a resulting reduction in dopamine levels in the brain. DA neuron degeneration and the risk of developing PD is connected to genetic mutations affiliated with lysosomal function and protein degradation. Accessible human cellular models for PD-relevant genetic mutations are needed to investigate mechanisms of DA cell death and define points of therapeutic intervention. Human induced pluripotent stem cell (iPSC)-derived midbrain DA neurons offer a developmentally and physiologically relevant in vitro model for investigating PD pathogenic mechanisms across genetic backgrounds. In this study, we generated DA neurons using iPSCs from two clinically diagnosed PD patients, one harboring an inherited GBAN370S mutation and the other a mutation in LRRK2G2019S and compared pathophysiology against DA neurons from genetically engineered SNCAA53T iPSCs and its isogenic apparently healthy normal (AHN) iPSCs. Our results present a novel phenotype for GBAN370S and LRRK2G2019S derived DA neurons, showing that they produced and released significantly more dopamine compared to the AHN and SNCAA53T mutant DA neurons. All mutant DA neurons developed deficient glucocerebrosidase (GCase) activity, increased mitochondrial stress, aberrant neuronal activity patterns, and increased -synuclein accumulation. Together these data suggest potentially divergent origins of PD pathogenesis in GBAN370S and LRRK2G2019S DA neurons. In addition, compound screening confirmed that GCase modulators can rescue enzyme activity and impact neural activity across all DA mutant neurons, to varying degrees. These data demonstrate unique in vitro phenotypes associated with PD and suggest a diversity of underlying mechanisms across different genetic backgrounds. Together, the cell lines used in this study present a valuable tool for new therapeutic discovery.
]]></description>
<dc:creator>Fathi, A.</dc:creator>
<dc:creator>Bakshy, K.</dc:creator>
<dc:creator>Zieghami, L.</dc:creator>
<dc:creator>Fiene, R.</dc:creator>
<dc:creator>Bradley, R.</dc:creator>
<dc:creator>Dickerson, S.</dc:creator>
<dc:creator>Carlson, C.</dc:creator>
<dc:creator>Schachtele, S.</dc:creator>
<dc:creator>Liu, J.</dc:creator>
<dc:date>2023-01-07</dc:date>
<dc:identifier>doi:10.1101/2023.01.06.521264</dc:identifier>
<dc:title><![CDATA[Diverging Parkinson's Disease Pathology between GBAN370S ,LRRK2G2019S and engineered SNCAA53T iPSC-derived Dopaminergic Neurons]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-07</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.04.531108v1?rss=1">
<title>
<![CDATA[
MerTK mediates the immunologically silent uptake of alpha-synuclein fibrils by human microglia 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.04.531108v1?rss=1"
</link>
<description><![CDATA[
MerTK is a receptor tyrosine kinase that mediates the immunologically silent phagocytic uptake of diverse types of cellular debris. Highly expressed on the surface of microglial cell, MerTK is of importance in brain development, homeostasis, plasticity, and disease. Yet, involvement of this receptor in the clearance of protein aggregates that accumulate with aging and in neurodegenerative diseases has yet to be defined. The current study explored the function of MerTK in the microglial uptake of alpha-synuclein fibrils which play a causative role in the pathobiology of synucleinopathies.

Using human primary and induced pluripotent stem cell-derived microglia, the MerTK- dependence of alpha-synuclein fibril internalization was investigated in vitro. Relevance of this pathway to synucleinopathies was assessed by analyzing MerTK expression in patient-derived cells and tissues.

Pharmacological inhibition of MerTK and siRNA-mediated MERTK knockdown both caused a decreased rate of alpha-synuclein fibril internalization by human microglia. Consistent with the immunologically silent nature of MerTK-mediated phagocytosis, alpha-synuclein fibril internalization did not induce secretion of pro-inflammatory cytokines from microglia. In addition, burden analysis in two independent patient cohorts revealed a significant association between rare functionally deleterious MERTK variants and Parkinsons disease in one of the cohorts (p = 0.002). Accordingly, MERTK expression was significantly upregulated in nigral microglia from Parkinsons disease/Lewy body dementia patients compared to those from non-neurological control donors in a single-nuclei RNA-sequencing dataset (p = 5.08x10-21), and MerTK protein expression positively correlated with alpha-synuclein level in human cortex lysates (p = 0.0029).

Taken together, our findings define a novel role for MerTK in mediating the uptake of alpha-synuclein aggregates by human microglia, with possible involvement in limiting alpha-synuclein spread in synucleinopathies such as Parkinsons disease.
]]></description>
<dc:creator>Dorion, M.-F.</dc:creator>
<dc:creator>Senkevich, K.</dc:creator>
<dc:creator>Yaqubi, M.</dc:creator>
<dc:creator>Kieran, N. W.</dc:creator>
<dc:creator>Chen, C. X.- Q.</dc:creator>
<dc:creator>MacDonald, A.</dc:creator>
<dc:creator>Luo, W.</dc:creator>
<dc:creator>Wallis, A.</dc:creator>
<dc:creator>Shlaifer, I.</dc:creator>
<dc:creator>Hall, J.</dc:creator>
<dc:creator>Dudley, R. W. R.</dc:creator>
<dc:creator>Glass, I. A.</dc:creator>
<dc:creator>Birth Defects Research Laboratory,</dc:creator>
<dc:creator>Straton, J. A.</dc:creator>
<dc:creator>Fon, E. A.</dc:creator>
<dc:creator>Bartels, T.</dc:creator>
<dc:creator>Antel, J. P.</dc:creator>
<dc:creator>Gan-Or, Z.</dc:creator>
<dc:creator>Durcan, T. M.</dc:creator>
<dc:creator>Healy, L. M.</dc:creator>
<dc:date>2023-03-05</dc:date>
<dc:identifier>doi:10.1101/2023.03.04.531108</dc:identifier>
<dc:title><![CDATA[MerTK mediates the immunologically silent uptake of alpha-synuclein fibrils by human microglia]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-05</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.16.524229v1?rss=1">
<title>
<![CDATA[
Modulatory Effect of Levodopa on the Basal Ganglia-Cerebellum Connectivity in Parkinson's Disease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.16.524229v1?rss=1"
</link>
<description><![CDATA[
Levodopa has remained the mainstay of medical therapy for Parkinsons disease since its development in the 1980s. However, long-term medication use is associated with declining clinical efficacy and the emergence of motor complications. Unveiling the effects of levodopa on brain functional reorganisation at a relatively early treatment phase is therefore imperative to inform the optimisation of Parkinsons therapeutics. In this study, we comprehensively investigated levodopas modulation on the resting-state functional connectivity in the cortico- basal ganglia-cerebellum system at regional and network levels, with dual cross-sectional and longitudinal designs. The data was extracted from the Parkinsons Progression Marker Initiative (PPMI) dataset. The cross-sectional patient groups comprised 17 Parkinsons patients on stable levodopa medication and 15 drug-naive patients, while the longitudinal set included 14 Parkinsons patients measured at both drug-naive and levodopa-medicated conditions. With nodes defined across cortical, basal ganglia, and cerebellar networks, we conducted univariate comparisons of the internodal connectivity strength between the medication conditions using nonparametric permutation. At the network level, we computed multivariate combinations of individual connections within and between the networks, followed by an assessment of their discriminative capabilities on patients medication classes using supervised machine learning. The univariate seed-based approach showed no statistically significant effect of levodopa in either dataset. However, the network connectivity pattern between basal ganglia and the cerebellum displayed a robust classification power in the longitudinal dataset and a similar trend was observed in the cross-sectional. The role of the cerebellum is often overlooked in previous functional integration investigations of Parkinsons disease and levodopa effects. Considering the recent evidence suggesting the bidirectional communications between the cerebellum and basal ganglia networks, our study provides further insight into the importance of inter-network functional connectivity in Parkinsons, as well as in the functional and plastic processes following levodopa medication.
]]></description>
<dc:creator>Abulikemu, S.</dc:creator>
<dc:creator>Tai, Y. F.</dc:creator>
<dc:creator>Haar, S.</dc:creator>
<dc:date>2023-01-18</dc:date>
<dc:identifier>doi:10.1101/2023.01.16.524229</dc:identifier>
<dc:title><![CDATA[Modulatory Effect of Levodopa on the Basal Ganglia-Cerebellum Connectivity in Parkinson's Disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.04.20.537553v1?rss=1">
<title>
<![CDATA[
Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.04.20.537553v1?rss=1"
</link>
<description><![CDATA[
The brain is spatially organized and contains unique cell types, each performing diverse functions, and exhibiting differential susceptibility to neurodegeneration. This is exemplified in Parkinsons disease with the preferential loss of dopaminergic neurons of the substantia nigra pars compacta. Using a Parkinsons transgenic model, we conducted a single-cell spatial transcriptomic and dopaminergic neuron translatomic analysis of young and old mouse brains. Through the high resolving capacity of single-cell spatial transcriptomics, we provide a deep characterization of the expression features of dopaminergic neurons and 27 other cell types within their spatial context, identifying markers of healthy and aging cells, spanning Parkinsons-relevant pathways. We integrate gene enrichment and GWAS data to prioritize putative causative genes for disease investigation, identifying CASR as a novel regulator of dopaminergic calcium handling. These datasets (see: spatialbrain.org) represent the largest public resource for the investigation of spatial gene expression in brain cells in health, aging and disease.
]]></description>
<dc:creator>Kilfeather, P.</dc:creator>
<dc:creator>Khoo, J. H.</dc:creator>
<dc:creator>Wagner, K.</dc:creator>
<dc:creator>Liang, H.</dc:creator>
<dc:creator>Caiazza, M.-C.</dc:creator>
<dc:creator>An, Y.</dc:creator>
<dc:creator>Zhang, X.</dc:creator>
<dc:creator>Chen, X.</dc:creator>
<dc:creator>Connor-Robson, N.</dc:creator>
<dc:creator>Shang, Z.</dc:creator>
<dc:creator>Wade-Martins, R.</dc:creator>
<dc:date>2023-04-20</dc:date>
<dc:identifier>doi:10.1101/2023.04.20.537553</dc:identifier>
<dc:title><![CDATA[Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-20</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.01.530566v1?rss=1">
<title>
<![CDATA[
Early striatal hyperexcitability in an in vitro human striatal microcircuit model carrying the Parkinson's GBA-N370S mutation 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.01.530566v1?rss=1"
</link>
<description><![CDATA[
Understanding medium spiny neuron (MSN) physiology is essential to understand motor impairments in Parkinsons disease (PD) given the architecture of the basal ganglia. Here, we developed a custom three-chamber microfluidic platform and established a cortico-striato-nigral microcircuit recapitulating the striatal presynaptic triad in vitro using induced pluripotent stem cell (iPSC)-derived neurons. We found that, although cortical glutamatergic projections facilitated MSN synaptic activity, dopaminergic transmission was essential for excitability maturation of MSNs in vitro. Replacement of wild-type iPSC-dopamine neurons (iPSC-DaNs) in the striatal microcircuit with those carrying the PD-related GBA-N370S mutation induced early hyperexcitability in iPSC-MSNs through reduction of voltage-gated sodium and potassium intrinsic currents. Such deficits were resolved in aged cultures or with antagonism of protein kinase A activity in nigrostriatal iPSC-DaNs. Hence, our results highlight the unique utility of modelling striatal neurons in a modular and highly physiological circuit which is essential to reveal mechanistic insights of the loss of electrical functional integrity in the striata of GBA1 PD patients.
]]></description>
<dc:creator>Do, Q. B.</dc:creator>
<dc:creator>Ng, B.</dc:creator>
<dc:creator>Marquez-Gomez, R.</dc:creator>
<dc:creator>Beccano-Kelly, D.</dc:creator>
<dc:creator>Ibarra-Aizpurua, N.</dc:creator>
<dc:creator>Caiazza, M.-C.</dc:creator>
<dc:creator>Lang, C.</dc:creator>
<dc:creator>Baleriola, J.</dc:creator>
<dc:creator>Bengoa-Vergniory, N.</dc:creator>
<dc:creator>Wade-Martins, R.</dc:creator>
<dc:date>2023-03-02</dc:date>
<dc:identifier>doi:10.1101/2023.03.01.530566</dc:identifier>
<dc:title><![CDATA[Early striatal hyperexcitability in an in vitro human striatal microcircuit model carrying the Parkinson's GBA-N370S mutation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.31.535090v1?rss=1">
<title>
<![CDATA[
Dysregulated Wnt and NFAT signaling in a Parkinson's disease LRRK2 G2019S knock-in model 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.31.535090v1?rss=1"
</link>
<description><![CDATA[
BackgroundParkinsons disease (PD) is a progressive late-onset neurodegenerative disease leading to physical and cognitive decline. Mutations of leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of PD. LRRK2 is a complex scaffolding protein with known regulatory roles in multiple molecular pathways. Two prominent examples of LRRK2-modulated pathways are Wingless/Int (Wnt) and nuclear factor of activated T-cells (NFAT) signaling. Both are well described key regulators of immune and nervous system development as well as maturation. The aim of this study was to establish the physiological and pathogenic role of LRRK2 in Wnt and NFAT signaling in the brain, as well as the potential contribution of the non-canonical Wnt/Calcium pathway.

MethodsIn vivo cerebral Wnt and NFATc1 signaling activity was quantified in LRRK2 G2019S mutant knock-in (KI) and LRRK2 knockout (KO) male and female mice with repeated measures over 28 weeks, employing lentiviral luciferase biosensors, and analyzed using a mixed-effect model. To establish spatial resolution, we investigated tissues, and primary neuronal cell cultures from different brain regions combining luciferase signaling activity, immunohistochemistry, qPCR and western blot assays. Results were analyzed by unpaired t-test with Welchs correction or 2-way ANOVA with post hoc corrections.

ResultsIn vivo Wnt signaling activity in LRRK2 KO and LRRK2 G2019S KI mice was increased significantly [~]3-fold, with a more pronounced effect in males ([~]4-fold) than females ([~]2-fold). NFATc1 signaling was reduced [~]0.5-fold in LRRK2 G2019S KI mice. Brain tissue analysis showed region-specific expression changes in Wnt and NFAT signaling components. These effects were predominantly observed at the protein level in the striatum and cerebral cortex of LRRK2 KI mice. Primary neuronal cell culture analysis showed significant genotype-dependent alterations in Wnt and NFATc1 signaling under basal and stimulated conditions. Wnt and NFATc1 signaling was primarily dysregulated in cortical and hippocampal neurons respectively.

ConclusionsOur study further built on knowledge of LRRK2 as a Wnt and NFAT signaling protein. We identified complex changes in neuronal models of LRRK2 PD, suggesting a role for mutant LRRK2 in the dysregulation of NFAT, and canonical and non-canonical Wnt signaling.
]]></description>
<dc:creator>Wetzel, A.</dc:creator>
<dc:creator>Lei, S. H.</dc:creator>
<dc:creator>Liu, T.</dc:creator>
<dc:creator>Hughes, M. P.</dc:creator>
<dc:creator>Peng, Y.</dc:creator>
<dc:creator>McKay, T.</dc:creator>
<dc:creator>Waddington, S. N.</dc:creator>
<dc:creator>Granno, S.</dc:creator>
<dc:creator>Rahim, A. A.</dc:creator>
<dc:creator>Harvey, K.</dc:creator>
<dc:date>2023-04-01</dc:date>
<dc:identifier>doi:10.1101/2023.03.31.535090</dc:identifier>
<dc:title><![CDATA[Dysregulated Wnt and NFAT signaling in a Parkinson's disease LRRK2 G2019S knock-in model]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-04-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.02.17.529028v1?rss=1">
<title>
<![CDATA[
Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.02.17.529028v1?rss=1"
</link>
<description><![CDATA[
Activating mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) cause Parkinsons disease. LRRK2 phosphorylates a subset of Rab GTPases, particularly Rab10 and Rab8A, and we showed previously that phosphoRabs play an important role in LRRK2 membrane recruitment and activation (Vides et al., 2022). To learn more about LRRK2 pathway regulation, we carried out an unbiased, CRISPR-based genome-wide screen to identify modifiers of cellular phosphoRab10 levels. A flow cytometry assay was developed to detect changes in phosphoRab10 levels in pools of mouse NIH-3T3 cells harboring unique CRISPR guide sequences. Multiple negative and positive regulators were identified; surprisingly, knockout of the Rab12 gene was especially effective in decreasing phosphoRab10 levels in multiple cell types and knockout mouse tissues. Rab-driven increases in phosphoRab10 were specific for Rab12, LRRK2 dependent and PPM1H phosphatase reversible; they were seen with wild type and pathogenic G2019S and R1441C LRRK2. AlphaFold modeling revealed a novel Rab12 binding site in the LRRK2 Armadillo domain and we show that residues predicted to be essential for Rab12 interaction at this site influence overall phosphoRab levels in a manner distinct from Rab29 activation of LRRK2. Our data support a model in which Rab12 binding to a new site in the LRRK2 Armadillo domain activates LRRK2 kinase for Rab phosphorylation and could serve as a new therapeutic target for a novel class of LRRK2 inhibitors that do not target the kinase domain.
]]></description>
<dc:creator>Dhekne, H. S.</dc:creator>
<dc:creator>Tonelli, F.</dc:creator>
<dc:creator>Yeshaw, W. M.</dc:creator>
<dc:creator>Chiang, C. Y.</dc:creator>
<dc:creator>Limouse, C.</dc:creator>
<dc:creator>Jaimon, E.</dc:creator>
<dc:creator>Purlyte, E.</dc:creator>
<dc:creator>Alessi, D. R.</dc:creator>
<dc:creator>Pfeffer, S. R.</dc:creator>
<dc:date>2023-02-18</dc:date>
<dc:identifier>doi:10.1101/2023.02.17.529028</dc:identifier>
<dc:title><![CDATA[Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-02-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.04.531072v1?rss=1">
<title>
<![CDATA[
L1 retrotransposons drive human neuronal transcriptome complexity and functional diversification 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.04.531072v1?rss=1"
</link>
<description><![CDATA[
The genetic mechanisms underlying the expansion in size and complexity of the human brain remains poorly understood. L1 retrotransposons are a source of divergent genetic information in hominoid genomes, but their importance in physiological functions and their contribution to human brain evolution is largely unknown. Using multi-omic profiling we here demonstrate that L1-promoters are dynamically active in the developing and adult human brain. L1s generate hundreds of developmentally regulated and cell-type specific transcripts, many which are co-opted as chimeric transcripts or regulatory RNAs. One L1-derived lncRNA, LINC01876, is a human-specific transcript expressed exclusively during brain development. CRISPRi-silencing of LINC01876 results in reduced size of cerebral organoids and premature differentiation of neural progenitors, implicating L1s in human-specific developmental processes. In summary, our results demonstrate that L1-derived transcripts provide a previously undescribed layer of primate- and human-specific transcriptome complexity that contributes to the functional diversification of the human brain.
]]></description>
<dc:creator>Garza, R.</dc:creator>
<dc:creator>Atacho, D.</dc:creator>
<dc:creator>Adami, A.</dc:creator>
<dc:creator>Gerdes, P.</dc:creator>
<dc:creator>Vinod, M.</dc:creator>
<dc:creator>Hsieh, P.</dc:creator>
<dc:creator>Karlsson, O.</dc:creator>
<dc:creator>Horvath, V.</dc:creator>
<dc:creator>Johansson, P. A.</dc:creator>
<dc:creator>Pandiloski, N.</dc:creator>
<dc:creator>Matas, J.</dc:creator>
<dc:creator>Quaegebeur, A.</dc:creator>
<dc:creator>Kouli, A.</dc:creator>
<dc:creator>Sharma, Y.</dc:creator>
<dc:creator>Jonsson, M. E.</dc:creator>
<dc:creator>Monni, E.</dc:creator>
<dc:creator>Englund, E.</dc:creator>
<dc:creator>Eichler, E. E.</dc:creator>
<dc:creator>Gale Hammell, M.</dc:creator>
<dc:creator>Barker, R. A.</dc:creator>
<dc:creator>Kokaia, Z.</dc:creator>
<dc:creator>Douse, C. H.</dc:creator>
<dc:creator>Jakobsson, J.</dc:creator>
<dc:date>2023-03-06</dc:date>
<dc:identifier>doi:10.1101/2023.03.04.531072</dc:identifier>
<dc:title><![CDATA[L1 retrotransposons drive human neuronal transcriptome complexity and functional diversification]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-06</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.04.531078v1?rss=1">
<title>
<![CDATA[
Tau protein aggregation associated with SARS-CoV-2 main protease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.04.531078v1?rss=1"
</link>
<description><![CDATA[
The primary function of virus proteases is the proteolytic processing of the viral polyprotein. These enzymes can also cleave host cell proteins, which is important for viral pathogenicity, modulation of cellular processes, viral replication, the defeat of antiviral responses and modulation of the immune response. It is known that COVID-19 can influence multiple tissues or organs and that infection can damage the functionality of the brain in multiple ways. After COVID-19 infections, amyloid-{beta}, neurogranin, tau and phosphorylated tau were detected extracellularly, implicating possible neurodegenerative processes.

The present study describes the possible induction of protein aggregation by the SARS-CoV-2 3CL protease (3CLpro) possibly relevant in neuropathology, such as aggregation of tau, alpha-synuclein and TPD-43. Further investigations demonstrated that tau was proteolytically cleaved by the viral protease 3CL and, consequently, generated aggregates. However, more evidence is needed to confirm that COVID-19 is able to trigger neurodegenerative diseases.
]]></description>
<dc:creator>Eberle, R. J.</dc:creator>
<dc:creator>Coronado, M. A.</dc:creator>
<dc:creator>Gering, I.</dc:creator>
<dc:creator>Korostov, K.</dc:creator>
<dc:creator>Stefanski, A.</dc:creator>
<dc:creator>Stuehler, K.</dc:creator>
<dc:creator>Kraemer-Schulien, V.</dc:creator>
<dc:creator>Bloemeke, L.</dc:creator>
<dc:creator>Bannach, O.</dc:creator>
<dc:creator>Willbold, D.</dc:creator>
<dc:date>2023-03-06</dc:date>
<dc:identifier>doi:10.1101/2023.03.04.531078</dc:identifier>
<dc:title><![CDATA[Tau protein aggregation associated with SARS-CoV-2 main protease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-06</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.21.525025v1?rss=1">
<title>
<![CDATA[
Adult-specific Reelin expression alters striatal neuronal organization. Implications for neuropsychiatric disorders. 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.21.525025v1?rss=1"
</link>
<description><![CDATA[
In addition to neuronal migration, brain development and adult plasticity, the extracellular matrix protein Reelin has been extensively implicated in human psychiatric disorders such as schizophrenia, bipolar disorder and autistic spectrum disorder. Moreover, heterozygous reeler mice exhibit features reminiscent of these disorders, while overexpression of Reelin protects against its manifestation. However, how Reelin influences the structure and circuits of the striatal complex, a key region for the above-mentioned disorders, is far from being understood, especially when altered Reelin expression levels are found at adult stages. In the present study, we took advantage of complementary conditional gain- and loss-of-function mouse models to investigate how Reelin levels may modify adult brains striatal structure and neuronal composition. Using immunohistochemical techniques, we determined that Reelin does not seem to influence the striatal patch and matrix organization (studied by -opioid receptor immunohistochemistry) nor the density of medium spiny neurons (MSNs, studied with DARPP-32). We show that overexpression of Reelin leads to increased numbers of striatal Parvalbumin- and Cholinergic-interneurons, and to a slight increase in the tyrosine hydroxylase-positive projections. We conclude that increased Reelin levels might modulate the numbers of striatal interneurons and the density of the nigrostriatal dopaminergic projections, suggesting that these changes may be involved in the protection of Reelin against neuropsychiatric disorders.
]]></description>
<dc:creator>Pardo, M.</dc:creator>
<dc:creator>Gregorio, S.</dc:creator>
<dc:creator>Montalban, E.</dc:creator>
<dc:creator>Pujadas, L.</dc:creator>
<dc:creator>Elias-Tersa, A.</dc:creator>
<dc:creator>Masachs, N.</dc:creator>
<dc:creator>Vilchez-Acosta, A.</dc:creator>
<dc:creator>Parent, A.</dc:creator>
<dc:creator>Auladell, C.</dc:creator>
<dc:creator>Girault, J. A.</dc:creator>
<dc:creator>Vila, M.</dc:creator>
<dc:creator>Nairn, A. C.</dc:creator>
<dc:creator>Manso, Y.</dc:creator>
<dc:creator>Soriano, E.</dc:creator>
<dc:date>2023-01-22</dc:date>
<dc:identifier>doi:10.1101/2023.01.21.525025</dc:identifier>
<dc:title><![CDATA[Adult-specific Reelin expression alters striatal neuronal organization. Implications for neuropsychiatric disorders.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-22</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.01.16.523926v1?rss=1">
<title>
<![CDATA[
The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinsons disease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.01.16.523926v1?rss=1"
</link>
<description><![CDATA[
Genetic variants conferring risk for Parkinsons disease have been highlighted through genome-wide association studies, yet exploration of their specific disease mechanisms is lacking. Two Parkinsons disease candidate genes, KAT8 and KANSL1, identified through genome-wide studies and a PINK1-mitophagy screen, encode part of the histone acetylating non-specific lethal complex. This complex localises to the nucleus, where it has a role in transcriptional activation, and to mitochondria, where it has been suggested to have a role in mitochondrial transcription. In this study, we sought to identify whether the non-specific lethal complex has potential regulatory relationships with other genes associated with Parkinsons disease in human brain.

Correlation in the expression of non-specific lethal genes and Parkinsons disease-associated genes was investigated in primary gene co-expression networks utilising publicly available transcriptomic data from multiple brain regions (provided by the Genotype-Tissue Expression Consortium and UK Brain Expression Consortium), whilst secondary networks were used to examine cell-type specificity. Reverse engineering of gene regulatory networks generated regulons of the complex, which were tested for heritability using stratified linkage disequilibrium score regression and then validated in vitro using the QuantiGene multiplex assay.

Significant clustering of non-specific lethal genes was revealed alongside Parkinsons disease-associated genes in frontal cortex primary co-expression modules. Both primary and secondary co-expression modules containing these genes were enriched for mainly neuronal cell types. Regulons of the complex contained Parkinsons disease-associated genes and were enriched for biological pathways genetically linked to disease. When examined in a neuroblastoma cell line, 41% of prioritised gene targets showed significant changes in mRNA expression following KANSL1 or KAT8 perturbation.

In conclusion, genes encoding the non-specific lethal complex are highly correlated with and regulate genes associated with Parkinsons disease. Overall, these findings reveal a potentially wider role for this protein complex in regulating genes and pathways implicated in Parkinsons disease.
]]></description>
<dc:creator>Hicks, A. R.</dc:creator>
<dc:creator>Reynolds, R. H.</dc:creator>
<dc:creator>O'Callaghan, B.</dc:creator>
<dc:creator>Garcia Ruiz, S.</dc:creator>
<dc:creator>Gil Martinez, A. L.</dc:creator>
<dc:creator>Botia, J. A.</dc:creator>
<dc:creator>Plun-Favreau, H.</dc:creator>
<dc:creator>Ryten, M.</dc:creator>
<dc:date>2023-01-18</dc:date>
<dc:identifier>doi:10.1101/2023.01.16.523926</dc:identifier>
<dc:title><![CDATA[The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinsons disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-01-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.03.24.534149v1?rss=1">
<title>
<![CDATA[
Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.03.24.534149v1?rss=1"
</link>
<description><![CDATA[
Increasing evidence points to post-translational modifications (PTMs) as key regulators of alpha-synuclein (-Syn) function in health and disease. However, whether these PTMs occur before or after -Syn pathology formation and their role in regulating -Syn toxicity remain unclear. In this study, we demonstrate that post-fibrillization nitration of -Syn fibrils induced their fragmentation, modified their surface and dynamic properties but not their structure, and nearly abolished their seeding activity in primary neurons and in vivo. Furthermore, we show that the dynamic and surface properties of the fibrils, rather than simply their length, are important determinants of -Syn fibril seeding activity. Altogether, our work demonstrates that post-aggregation modifications of -Syn may provide novel approaches to target a central process that contributes to pathology formation and disease progression. Finally, our results suggest that the pattern of PTMs on pathological aggregates, rather than simply their presence, could be a key determinant of their toxicity and neurodegeneration. This calls for reconsidering current approaches relying solely on quantifying and correlating the level of pathology to assess the efficacy of novel therapies, as not all -Syn aggregates in the brain are pathogenic.
]]></description>
<dc:creator>Donzelli, S.</dc:creator>
<dc:creator>OSullivan, S.</dc:creator>
<dc:creator>Mahul-Mellier, A.-L.</dc:creator>
<dc:creator>Ulusoy, A.</dc:creator>
<dc:creator>Fusco, G.</dc:creator>
<dc:creator>Kumar, S. T.</dc:creator>
<dc:creator>Chiki, A.</dc:creator>
<dc:creator>Burtscher, J.</dc:creator>
<dc:creator>Boussouf, M. L. D.</dc:creator>
<dc:creator>Rostami, I.</dc:creator>
<dc:creator>De Simone, A. D. S.</dc:creator>
<dc:creator>Di Monte, D. A.</dc:creator>
<dc:creator>Lashuel, H. A.</dc:creator>
<dc:date>2023-03-25</dc:date>
<dc:identifier>doi:10.1101/2023.03.24.534149</dc:identifier>
<dc:title><![CDATA[Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-03-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2023.10.12.562142v1?rss=1">
<title>
<![CDATA[
Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2023.10.12.562142v1?rss=1"
</link>
<description><![CDATA[
Synaptojanin-1 (SJ1) is a major neuronal-enriched PI(4,5)P2 4- and 5-phosphatase implicated in the shedding of endocytic factors during endocytosis. A mutation (R258Q) that impairs selectively its 4-phosphatase activity causes Parkinsonism in humans and neurological defects in mice (SJ1RQKI mice). Studies of these mice showed, besides an abnormal assembly state of endocytic factors at synapses, the presence of dystrophic nerve terminals selectively in a subset of nigro-striatal dopamine (DA)-ergic axons, suggesting a special lability of DA neurons to the impairment of SJ1 function. Here we have further investigated the impact of SJ1 on DA neurons using iPSC-derived SJ1 KO and SJ1RQKI DA neurons and their isogenic controls. In addition to the expected enhanced clustering of endocytic factors in nerve terminals, we observed in both SJ1 mutant neuronal lines increased cilia length. Further analysis of cilia of SJ1RQDA neurons revealed abnormal accumulation of the Ca2+ channel Cav1.3 and of ubiquitin chains, suggesting an impaired clearing of proteins from cilia which may result from an endocytic defect at the ciliary base, where a focal concentration of SJ1 was observed. We suggest that SJ1 may contribute to the control of ciliary protein dynamics in DA neurons, with implications on cilia-mediated signaling.
]]></description>
<dc:creator>Mohd Rafiq, N.</dc:creator>
<dc:creator>Fujise, K.</dc:creator>
<dc:creator>Rosenfeld, M.</dc:creator>
<dc:creator>Xu, P.</dc:creator>
<dc:creator>Wu, Y.</dc:creator>
<dc:creator>De Camilli, P.</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:identifier>doi:10.1101/2023.10.12.562142</dc:identifier>
<dc:title><![CDATA[Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2023-10-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2024.05.14.594262v1?rss=1">
<title>
<![CDATA[
Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX Reprograming 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2024.05.14.594262v1?rss=1"
</link>
<description><![CDATA[
Synovial sarcoma (SyS) is an aggressive soft-tissue malignancy characterized by a pathognomonic chromosomal translocation leading to the formation of the SS18::SSX fusion oncoprotein. SS18::SSX associates with mammalian BAF complexes suggesting deregulation of chromatin architecture as the oncogenic driver in this tumour type. To examine the epigenomic state of SyS we performed comprehensive multi-omics analysis on 52 primary pre-treatment human SyS tumours. Our analysis revealed a continuum of epigenomic states across the cohort at fusion target genes independent of rare somatic genetic lesions. We identify cell-of-origin signatures defined by enhancer states and reveal unexpected relationships between H2AK119Ub1 and active marks. The number of bivalent promoters, dually marked by the repressive H3K27me3 and activating H3K4me3 marks, has strong prognostic value and outperforms tumor grade in predicting patient outcome. Finally, we identify SyS defining epigenomic features including H3K4me3 expansion associated with striking promoter DNA hypomethylation in which SyS displays the lowest mean methylation level of any sarcoma subtype. We explore these distinctive features as potential vulnerabilities in SyS and identify H3K4me3 inhibition as a promising therapeutic strategy.
]]></description>
<dc:creator>Hofvander, J.</dc:creator>
<dc:creator>Qiu, A.</dc:creator>
<dc:creator>Lee, K.</dc:creator>
<dc:creator>Bilenky, M.</dc:creator>
<dc:creator>Carles, A.</dc:creator>
<dc:creator>Cao, Q.</dc:creator>
<dc:creator>Moksa, M.</dc:creator>
<dc:creator>Steif, J.</dc:creator>
<dc:creator>Su, E.</dc:creator>
<dc:creator>Sotiriou, A.</dc:creator>
<dc:creator>Goytain, A.</dc:creator>
<dc:creator>Hill, L.</dc:creator>
<dc:creator>Singer, S.</dc:creator>
<dc:creator>Andulis, I.</dc:creator>
<dc:creator>Wunder, J.</dc:creator>
<dc:creator>Mertens, F.</dc:creator>
<dc:creator>Banito, A.</dc:creator>
<dc:creator>Jones, K. B.</dc:creator>
<dc:creator>Underhill, T. M.</dc:creator>
<dc:creator>Nielsen, T.</dc:creator>
<dc:creator>Hirst, M.</dc:creator>
<dc:date>2024-05-17</dc:date>
<dc:identifier>doi:10.1101/2024.05.14.594262</dc:identifier>
<dc:title><![CDATA[Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX Reprograming]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2024-05-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2022.07.22.501196v1?rss=1">
<title>
<![CDATA[
Regulatory roles of three-dimensional structures of topologically associating domains 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2022.07.22.501196v1?rss=1"
</link>
<description><![CDATA[
1Transcriptional enhancers usually, but not always, regulate genes within the same topologically associating domain (TAD). We hypothesize that this incomplete insulation is due to three-dimensional structures of corresponding chromatin domains in individual cells: Whereas enhancers and genes buried inside the "core" of a domain interact mostly with other regions in the same domain, those on the "surface" can more easily interact with the outside. Here we show that a simple measure, the intra-TAD ratio, can quantify the "coreness" of a region with respect to single-cell domains it belongs. We show that domain surfaces are permissive for high gene expression, and cell type-specific active cis-regulatory elements (CREs), active histone marks, and transcription factor binding sites are enriched on domain surfaces, most strongly in chromatin subcompartments typically considered inactive. These findings suggest a "domain surface CRE" model of gene regulation. We also find that disease-associated non-coding variants are enriched on domain surfaces.
]]></description>
<dc:creator>Li, K. Y.</dc:creator>
<dc:creator>Cao, Q.</dc:creator>
<dc:creator>Wang, H.</dc:creator>
<dc:creator>Leung, D. C. Y.</dc:creator>
<dc:creator>Yip, K. Y.</dc:creator>
<dc:date>2022-07-23</dc:date>
<dc:identifier>doi:10.1101/2022.07.22.501196</dc:identifier>
<dc:title><![CDATA[Regulatory roles of three-dimensional structures of topologically associating domains]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2022-07-23</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2024.07.09.602700v1?rss=1">
<title>
<![CDATA[
Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2024.07.09.602700v1?rss=1"
</link>
<description><![CDATA[
BackgroundATP10B, a transmembrane lipid flippase located in late endosomes and lysosomes, facilitates the export of glucosylceramide and phosphatidylcholine by coupling this process to ATP hydrolysis. Recently, loss-of-function mutations in the ATP10B gene have been identified in Parkinsons disease patients, pointing to ATP10B as a candidate genetic risk factor. Previous studies have shown compromised lysosomal functionality upon ATP10B knockdown in human cell lines and primary cortical neurons. However, its role in vivo and specifically in the nigrostriatal dopaminergic system remains poorly understood.

MethodsTo investigate the role ATP10B in PD neuropathology, we induced ATP10B knockdown specifically in substantia nigra pars compacta neurons of rats using viral vector technology. Two different microRNA-based shRNA constructs targeting distinct regions of the ATP10B mRNA were used to cross-validate the findings. Behavioral evaluation, dopamine transporter 18F-FE-PE2I positron emission tomography imaging and neuropathological examination of the nigrostriatal pathway at one year post-injection were conducted. Additionally, midbrain neuronal cultures derived from ATP10B knock-out human induced pluripotent stem cells clones were used to study the impact of ATP10B loss in dopaminergic neurons in a more translational model.

ResultsATP10B knockdown in rat brain induced Parkinsonian motor deficits, and longitudinal striatal dopamine transporter 18F-FE-PE2I PET imaging revealed a progressive decrease in binding potential. Immunohistochemical analysis conducted one year post-injection confirmed the loss of dopaminergic terminals in the striatum, alongside a loss of dopaminergic neurons in the substantia nigra pars compacta. The expression of LAMP1, LAMP2a, cathepsin B and glucocerebrosidase was studied by immunofluorescence in the surviving dopaminergic neurons. A decrease in lysosomal numbers and an increase in lysosomal volume were observed more consistently in one of the knockdown constructs. The vulnerability of dopaminergic neurons to ATP10B loss-of-function was also observed in midbrain neuronal cultures derived from ATP10B knock-out human induced pluripotent stem cells clones, which showed a significant reduction in TH-positive neurons.

ConclusionTaken together, our findings demonstrate that ATP10B depletion detrimentally impacts the viability of dopaminergic neurons both in vivo and in vitro. Moreover, a broader impact on the functionality of the nigrostriatal pathway was evidenced as rats with ATP10B knockdown exhibited motor impairments similar to those observed in PD patients.
]]></description>
<dc:creator>Sanchiz-Calvo, M.</dc:creator>
<dc:creator>Coccia, E.</dc:creator>
<dc:creator>Cawthorne, C.</dc:creator>
<dc:creator>Parfitt, G.</dc:creator>
<dc:creator>Van Laere, K.</dc:creator>
<dc:creator>Torre-Muruzabal, T.</dc:creator>
<dc:creator>Cabezudo, D.</dc:creator>
<dc:creator>Tsafaras, G.</dc:creator>
<dc:creator>Cascalho, A.</dc:creator>
<dc:creator>Van Den Haute, C.</dc:creator>
<dc:creator>Vangheluwe, P.</dc:creator>
<dc:creator>Blanchard, J.</dc:creator>
<dc:creator>Bentea, E.</dc:creator>
<dc:creator>Baekelandt, V.</dc:creator>
<dc:date>2024-07-13</dc:date>
<dc:identifier>doi:10.1101/2024.07.09.602700</dc:identifier>
<dc:title><![CDATA[Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2024-07-13</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2024.07.01.601474v1?rss=1">
<title>
<![CDATA[
The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases uncovers cholesterol as a regulator of astrocyte reactivity impaired by ApoE4 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2024.07.01.601474v1?rss=1"
</link>
<description><![CDATA[
Lipid changes in the brain have been implicated in many neurodegenerative diseases including Alzheimers Disease (AD), Parkinsons disease and Amyotrophic Lateral Sclerosis. To facilitate comparative lipidomic research across brain-diseases we established a data commons named the Neurolipid Atlas, that we have pre-populated with novel human, mouse and isogenic induced pluripotent stem cell (iPSC)-derived lipidomics data for different brain diseases. We show that iPSC-derived neurons, microglia and astrocytes display distinct lipid profiles that recapitulate in vivo lipotypes. Leveraging multiple datasets, we show that the AD risk gene ApoE4 drives cholesterol ester (CE) accumulation in human astrocytes recapitulating CE accumulation measured in the human AD brain. Multi-omic interrogation of iPSC-derived astrocytes revealed that cholesterol plays a major role in astrocyte interferon-dependent pathways such as the immunoproteasome and major histocompatibility complex (MHC) class I antigen presentation. We show that through enhanced cholesterol esterification ApoE4 suppresses immune activation of astrocytes. Our novel data commons, available at neurolipidatlas.com, provides a user-friendly tool and knowledge base for a better understanding of lipid dyshomeostasis in neurodegenerative diseases.
]]></description>
<dc:creator>Feringa, F. M.</dc:creator>
<dc:creator>Koppes-den Hertog, S. J.</dc:creator>
<dc:creator>Wang, L.</dc:creator>
<dc:creator>Derks, R. J. E.</dc:creator>
<dc:creator>Kruijff, I.</dc:creator>
<dc:creator>Erlebach, L.</dc:creator>
<dc:creator>Heijneman, J.</dc:creator>
<dc:creator>Miramontes, R.</dc:creator>
<dc:creator>Pömpner, N.</dc:creator>
<dc:creator>Blomberg, N.</dc:creator>
<dc:creator>Olivier-Jimenez, D.</dc:creator>
<dc:creator>Johanson, L. E.</dc:creator>
<dc:creator>Cammack, A. J.</dc:creator>
<dc:creator>Giblin, A.</dc:creator>
<dc:creator>Toomey, C. E.</dc:creator>
<dc:creator>Rose, I. V. L.</dc:creator>
<dc:creator>Yuan, H.</dc:creator>
<dc:creator>Ward, M. E.</dc:creator>
<dc:creator>Isaacs, A.</dc:creator>
<dc:creator>Kampmann, M.</dc:creator>
<dc:creator>Kronenberg-Versteeg, D.</dc:creator>
<dc:creator>Lashley, T.</dc:creator>
<dc:creator>Thompson, L. M.</dc:creator>
<dc:creator>Ori, A.</dc:creator>
<dc:creator>Mohammed, Y.</dc:creator>
<dc:creator>Giera, M.</dc:creator>
<dc:creator>van der Kant, R. H. N.</dc:creator>
<dc:date>2024-07-03</dc:date>
<dc:identifier>doi:10.1101/2024.07.01.601474</dc:identifier>
<dc:title><![CDATA[The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases uncovers cholesterol as a regulator of astrocyte reactivity impaired by ApoE4]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2024-07-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2024.06.25.600616v1?rss=1">
<title>
<![CDATA[
Presynaptic GABAA receptors control integration of nicotinic input onto dopaminergic axons in the striatum 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2024.06.25.600616v1?rss=1"
</link>
<description><![CDATA[
Axons of dopaminergic neurons express gamma-aminobutyric acid type-A receptors (GABAARs) and nicotinic acetylcholine receptors (nAChRs) which are both independently positioned to shape striatal dopamine release. Using electrophysiology and calcium imaging, we investigated how interactions between GABAARs and nAChRs influence dopaminergic axon excitability. Direct axonal recordings showed that benzodiazepine application suppresses subthreshold axonal input from cholinergic interneurons (CINs). In imaging experiments, we used the first temporal derivative of presynaptic calcium signals to distinguish between direct- and nAChR-evoked activity in dopaminergic axons. We found that GABAAR antagonism with gabazine selectively enhanced nAChR-evoked axonal signals. Acetylcholine release was unchanged in gabazine suggesting that GABAARs located on dopaminergic axons, but not CINs, mediated this enhancement. Unexpectedly, we found that a widely used GABAAR antagonist, picrotoxin, inhibits axonal nAChRs and should be used cautiously for striatal circuit analysis. Overall, we demonstrate that GABAARs on dopaminergic axons regulate integration of nicotinic input to shape presynaptic excitability.
]]></description>
<dc:creator>Brill-Weil, S. G.</dc:creator>
<dc:creator>Kramer, P. F.</dc:creator>
<dc:creator>Yanez, A.</dc:creator>
<dc:creator>Clever, F. H.</dc:creator>
<dc:creator>Zhang, R.</dc:creator>
<dc:creator>Khaliq, Z. M.</dc:creator>
<dc:date>2024-06-25</dc:date>
<dc:identifier>doi:10.1101/2024.06.25.600616</dc:identifier>
<dc:title><![CDATA[Presynaptic GABAA receptors control integration of nicotinic input onto dopaminergic axons in the striatum]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2024-06-25</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://biorxiv.org/cgi/content/short/2024.06.18.598931v1?rss=1">
<title>
<![CDATA[
A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal infection in a PINK1KO mouse model of Parkinsons disease 
]]>
</title>
<link>
https://biorxiv.org/cgi/content/short/2024.06.18.598931v1?rss=1"
</link>
<description><![CDATA[
Parkinsons disease (PD) is characterized by a protracted period of non-motor symptoms, including gastrointestinal (GI) dysfunction, which can precede the development of the cardinal motor deficits by decades. This long prodrome of disease is highly suggestive of immune cell involvement in the initiation of disease, but currently the field lacks robust model systems to study such mechanisms. It has been hypothesized that pathology may be first initiated in the periphery due to environmental triggers, such as pathogens that enter the GI tract. We further speculate that the impact of such pathogens on the immune system could be exacerbated in genetically predisposed individuals. Our group has developed a GI-targeted pathogen-induced PD mouse model system in PINK1 KO mice with Gram-negative bacterial infections and found that T cells are a major player in driving PD-like motor symptoms at late stages following infection. Herein, we now map the initiating immune events at the site of infection at the earliest stages with the goal of shedding light on the earliest mechanisms triggering immune-mediated pathological processes relevant to PD. Using unbiased single cell sequencing, we demonstrate that myeloid cells are the earliest dysregulated immune cell type in PINK1 KO infected mice at 1-week post-infection, followed by a dysregulated T cell response shortly after, at 2 weeks post-infection. We find that these myeloid cells have an enhanced proinflammatory profile, are more mature, and develop enhanced capacity for antigen presentation. Using unbiased prediction analysis, our data suggest that cytotoxic T cells and myeloid cells are particularly poised for interacting with each other, and we identify possible direct cell-cell interaction pathways that might be implicated. Taken together, deciphering the earliest immune mechanisms in the periphery underpinning PD autoimmunity will be instrumental in the development of effective therapeutic targeting strategies before irrevocable neuronal damage ensues.
]]></description>
<dc:creator>Recinto, S.</dc:creator>
<dc:creator>Kazanova, A.</dc:creator>
<dc:creator>MacDonald, A.</dc:creator>
<dc:creator>Afanasiev, E.</dc:creator>
<dc:creator>Premachandran, S.</dc:creator>
<dc:creator>Allot, A.</dc:creator>
<dc:creator>Bessaiah, H.</dc:creator>
<dc:creator>Cordeiro, B.</dc:creator>
<dc:creator>Mukherjee, S.</dc:creator>
<dc:creator>Pei, J.</dc:creator>
<dc:creator>McBride, H. M.</dc:creator>
<dc:creator>Trudeau, L.-E.</dc:creator>
<dc:creator>Gruenheid, S.</dc:creator>
<dc:creator>Stratton, J. A.</dc:creator>
<dc:date>2024-06-22</dc:date>
<dc:identifier>doi:10.1101/2024.06.18.598931</dc:identifier>
<dc:title><![CDATA[A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal infection in a PINK1KO mouse model of Parkinsons disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2024-06-22</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
